var title_f9_31_9712="Mycoplasma chest x-ray";
var content_f9_31_9712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mycoplasma pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows poorly-defined nodular opacities in the right lower lung zone. The patient was a 30-year-old woman with Mycoplasma pneumoniae pneumonia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Viruses, Mycoplasma, and Chlamydia. In: Imaging of Pulmonary Infections, M&uuml;ller NL, Franquet T, Lee KS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9712=[""].join("\n");
var outline_f9_31_9712=null;
var title_f9_31_9713="Scabies infant foot";
var content_f9_31_9713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies, infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rash of scabies may be more diffuse in infants, spreading to the trunk and scalp in addition to the extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher, GR, Ludwig, S, Baskin, MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy;2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9713=[""].join("\n");
var outline_f9_31_9713=null;
var title_f9_31_9714="Diagnostic algorithm DMD and BMD";
var content_f9_31_9714=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 643px\">",
"   <div class=\"ttl\">",
"    Algorithm for the diagnosis of Duchenne and Becker muscular dystrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 623px; height: 719px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dashed lines indicate optional paths.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Darras BT, Scientific American Medicine. Scientific American 1993; 3:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9714=[""].join("\n");
var outline_f9_31_9714=null;
var title_f9_31_9715="Gonadorelin acetate: Drug information";
var content_f9_31_9715=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"21\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gonadorelin acetate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/44/41667?source=see_link\">",
"    see \"Gonadorelin acetate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lutrepulse&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F177075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gonadotropin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F177042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Primary hypothalamic amenorrhea:",
"     </b>",
"     Females: I.V., SubQ.: Initial dose: 5 mcg every 90 minutes via suitable pulsatile pump. Dosage adjustments may be made every 21 days if necessary.  An increase in dosage may be necessary if no response after 3 treatment intervals. In clinical trials, doses of 1-20 mcg were successfully administered. Treatment should be continued for 2 weeks after ovulation to maintain the corpus luteum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Appropriate vial should be selected for individualized treatment. Typical dose (5 mcg) is delivered with use of 0.8 mg vial.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F11300779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lutrepulse&trade;: 0.8 mg, 3.2 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11300326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F177025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Administer I.V. or SubQ using a suitable pulsatile pump. Set the pump to deliver 25-50 mcL of solution, based upon the dose, over a pulse period of 1 minute and a pulse frequency of 90 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F177024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction of ovulation in females with hypothalamic amenorrhea",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F177073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Local: Injection site irritation, superficial thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, anaphylactic reaction, anaphylactic shock, antibody formation (with long term therapy resulting in therapy failure), fever, headache, injection site reddening, injection site thrombophlebitis (mild and severe), menstrual bleeding increased, ovarian hyperstimulation (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F177028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gonadorelin or any component of the formulation; women with any condition (eg, pituitary prolactinoma) that could be exacerbated by pregnancy; patients who have ovarian cysts; any condition (eg, hormone-dependent tumor) that may be worsened by reproductive hormones",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F177013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported rarely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer:",
"     <b>",
"      [Canadian Boxed Warning]: Ovarian cancer has been reported in a very small number of infertile women treated with fertility drugs. A causal relationship has not been established.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian hyperstimulation syndrome (OHSS):",
"     <b>",
"      [Canadian Boxed Warning]: OHSS is a risk of ovulation induction therapy although it is rare with pulsatile gonadotropin releasing hormone (GnRH) therapy. Discontinue therapy if OHSS occurs; spontaneous resolution may be expected.",
"     </b>",
"     Clinicians should be alert for evidence of ascites, pleural effusion, fluid/electrolyte imbalance, hemoconcentration, cyst rupture, sepsis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician: Therapy should only be conducted by clinicians familiar with infertility problems and their management.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple births: May result from the use of these medications; advise patients of the potential risk of multiple births before starting treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F177017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11300324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The risk of fetal harm appears remote if gonadorelin is used during pregnancy. Clinical studies of pregnant women have not demonstrated an increased risk of fetal abnormalities during the first trimester. Follow-up reports of infants born to exposed mothers revealed no adverse effects or complications attributed to gonadorelin therapy. Based on its indicated use, gonadorelin treatment is continued for 2 weeks following ovulation to maintain the corpus luteum; initiation of treatment is not appropriate if pregnancy has been established.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11300325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F177021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ovarian ultrasound at baseline and at least weekly while on therapy or until ovulation is confirmed; LH, FSH, estradiol, progesterone (midluteal phase); basal body temperature;  injection site",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cryptocur (GR, NL);",
"     </li>",
"     <li>",
"      HRF (BE, GB, IE, LU);",
"     </li>",
"     <li>",
"      Kryptocur (BE, CH, CZ, DE, HN, HR, IT, LU);",
"     </li>",
"     <li>",
"      LH-RH Tanabe (TW);",
"     </li>",
"     <li>",
"      Luforan (BE, ES);",
"     </li>",
"     <li>",
"      Lutamin (JP);",
"     </li>",
"     <li>",
"      Lutrelef (BE, CH, FR, HU, PL, SE, SG);",
"     </li>",
"     <li>",
"      Relefact (CZ, GR, IE);",
"     </li>",
"     <li>",
"      Relefact LH-RH (AT, KP, NL);",
"     </li>",
"     <li>",
"      Relisorm L (BR, HU);",
"     </li>",
"     <li>",
"      Wyeth-Ayerst HRF (AU);",
"     </li>",
"     <li>",
"      Zyklomat (MY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F177012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates the release of luteinizing hormone (LH) from the anterior pituitary gland",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F177027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Response to therapy usually observed within 2-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~10-15 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily renal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: ~10-40 minutes; increased in patients with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kesrouani A, Abdallah MA, Attieh E, et al, &ldquo;Gonadotropin-Releasing Hormone for Infertility in Women with Primary Hypothalamic Amenorrhea. Toward a More-Interventional Approach,&rdquo;",
"      <i>",
"       J Reprod Med",
"      </i>",
"      , 2001, 46(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/31/9715/abstract-text/11209627/pubmed\" id=\"11209627\" target=\"_blank\">",
"        11209627",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15998 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-235EC14115-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9715=[""].join("\n");
var outline_f9_31_9715=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177038\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177075\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177042\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11300779\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11300326\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177025\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177024\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177073\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177028\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177013\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299419\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177017\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11300324\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11300325\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177021\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038649\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177012\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177027\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15998\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15998|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/44/41667?source=related_link\">",
"      Gonadorelin acetate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_31_9716="Chloroprocaine: Pediatric drug information";
var content_f9_31_9716=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chloroprocaine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?3/17/3350?source=see_link\">",
"    see \"Chloroprocaine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/60/43971?source=see_link\">",
"    see \"Chloroprocaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nesacaine&reg;;",
"     </li>",
"     <li>",
"      Nesacaine&reg;-MPF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nesacaine&reg;-CE",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1004946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Local Anesthetic, Injectable",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1004975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/17/3350?source=see_link\">",
"      see \"Chloroprocaine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose varies with procedure, desired depth, and duration of anesthesia, desired muscle relaxation, vascularity of tissues, physical condition, and age of patient. The smallest dose and concentration required to produce the desired effect should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Children &gt;3 years: Maximum dose without epinephrine: 11 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Maximum dose: 11 mg/kg; not to exceed 800 mg per treatment; with epinephrine: 14 mg/kg; not to exceed 1000 mg per treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infiltration and peripheral nerve block:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mandibular: 2-3 mL (40-60 mg) using 2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infraorbital: 0.5-1 mL (10-20 mg) using 2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brachial plexus: 30-40 mL (600-800 mg) using 2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Digital (without epinephrine): 3-4 mL (30-40 mg) using 1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pudendal: 10 mL (200 mg) into each side (2 sites) using 2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paracervical: 3 mL (30 mg) per each of four sites using 1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caudal and lumbar epidural block:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caudal: 15-25 mL using 2% to 3% solution; may repeat dose at 40- to 60-minute intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lumbar: 2-2.5 mL per segment using 2% to 3% solution; usual total volume 15-25 mL; repeated doses 2-6 mL less than the original dose may be given at 40- to 50-minutes intervals",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 2% [20 mg/mL] (30 mL [DSC]); 3% [30 mg/mL] (30 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nesacaine&reg;: 1% [10 mg/mL] (30 mL); 2% [20 mg/mL] (30 mL) [contains edetate disodium, methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 2% [20 mg/mL] (20 mL); 3% [30 mg/mL] (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nesacaine&reg;-MPF: 2% [20 mg/mL] (20 mL); 3% [30 mg/mL] (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1004979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer in small incremental doses; when using continuous intermittent catheter techniques, use frequent aspirations before and during the injection to avoid intravascular injection",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1004964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light. Solutions may not be resterilized by autoclaving.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1004947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Production of local or regional analgesia and anesthesia by local infiltration and peripheral nerve block techniques",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nesacaine&reg; may be confused with Neptazane&trade;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F149735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrest, hypotension, ventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, restlessness, seizure, tinnitus, unconsciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, erythema, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chondrolysis (continuous intra-articular administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactoid reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1004951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chloroprocaine, PABA, any anesthetic of the ester type, or any component of the formulation; cerebrospinal diseases such as meningitis or syphilis, and septicemia (spinal anesthetic use)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4370090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution as lumbar or caudal anesthesia in patients with existing neurologic disease, spinal deformities, or severe hypertension; use with caution in patients with hypotension, cardiac disease, and hepatic or renal disease. Use caution in debilitated, elderly, or acutely-ill patients; dose reduction may be required. Adverse effects in the CNS and cardiovascular system are directly related to the blood level of procaine, route of administration, and physical status of the patient and more likely to occur after systemic administration rather than infiltration.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1004952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Convulsions and cardiac arrhythmias resulting in cardiac arrest have been reported, presumably due to systemic toxicity following unintentional I.V. injection; should be administered in small incremental doses. Chloroprocaine solutions containing preservatives (methylparaben) are not to be used for lumbar or caudal anesthesia. When using for obstetrical anesthesia, 5% to 10% of cases where initial total doses of 120-400 mg were administered, have been associated with fetal bradycardia. Chondrolysis has been reported following continuous intra-articular infusion; intra-articular administration of local anesthetics is not an FDA-approved route of administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F149691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F149702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Local anesthetics rapidly cross the placenta and may cause varying degrees of maternal, fetal, and neonatal toxicity. Close maternal and fetal monitoring (heart rate and electronic fetal monitoring advised) are required during obstetrical use. Maternal hypotension has resulted from regional anesthesia. Positioning the patient on her left side and elevating the legs may help. Epidural, paracervical, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. The use of some local anesthetic drugs during labor and delivery may diminish muscle strength and tone for the first day or two of life. Administration as a paracervical block is not recommended with toxemia of pregnancy, fetal distress, or prematurity. Administration of a paracervical block early in pregnancy has resulted in maternal seizures and cardiovascular collapse. Fetal bradycardia and acidosis also have been reported. Fetal depression has occurred following unintended fetal intracranial injection while administering a paracervical and/or pudendal block.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1004981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, respiration, signs of CNS toxicity (lightheadedness, dizziness, tinnitus, restlessness, tremors, twitching, drowsiness, circumoral paresthesia)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1004967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4370091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Onset of action: 6-12 minutes",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Duration (patient, type of block, concentration, and method of anesthesia dependent): Up to 1 hour",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1004969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly hydrolyzed by plasma enzymes to 2-chloro-4-aminobenzoic acid and 8-diethylaminoethanol (80% conjugated before elimination)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life (",
"     <i>",
"      in vitro",
"     </i>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 43 &plusmn; 2 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adult males: 21 &plusmn; 2 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adult females: 25 &plusmn; 1 second",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Very little excreted as unchanged drug in urine; metabolites: Cloro-aminobenzoic acid and diethylaminoethanol primarily excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1004984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/60/43971?source=see_link\">",
"      see \"Chloroprocaine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     You will experience decreased sensation to pain, heat, or cold in the area and/or decreased muscle strength (depending on area of application) until effects wear off; use necessary caution to reduce incidence of possible injury until full sensation returns. Report irritation, pain, burning at injection site; chest pain or palpitations; or respiratory difficulty.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13023 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9716=[""].join("\n");
var outline_f9_31_9716=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149713\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149714\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004946\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004975\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149695\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149680\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004979\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004964\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004947\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149737\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149735\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004951\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370090\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004952\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299021\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149689\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149691\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149702\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004981\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004967\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370091\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004969\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004984\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13023\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13023|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/17/3350?source=related_link\">",
"      Chloroprocaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/60/43971?source=related_link\">",
"      Chloroprocaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_31_9717="Decerebrate and decorticate postures";
var content_f9_31_9717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Decorticate/decerebrate postures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9717=[""].join("\n");
var outline_f9_31_9717=null;
var title_f9_31_9718="Approach to the patient with postoperative jaundice";
var content_f9_31_9718=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with postoperative jaundice",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9718/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9718/contributors\">",
"     Scott A Fink, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9718/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9718/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9718/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9718/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/31/9718/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative jaundice, the presence of bilirubin elevation with or without clinical icterus appearing in the period following surgery, occurs as a result of numerous causes. This topic review will provide an overview of postoperative jaundice and a suggested approach for evaluation and management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no widely accepted classification of postoperative jaundice. Nevertheless, postoperative jaundice can be considered as part of a spectrum of abnormal liver biochemical tests, which are common in the postoperative period. A subset of patients who develop abnormal liver biochemical tests have preexisting liver disease, increasing their vulnerability to further hepatic injury from a variety of causes. Others develop liver biochemical abnormalities without preexisting liver disease. The distinction is potentially important since it can help clarify contributing causes, influence prognosis, and may guide long-term management.",
"   </p>",
"   <p>",
"    We have found it useful conceptually to subdivide postoperative jaundice into three categories: prehepatic, intrahepatic, and posthepatic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prehepatic, which results from overproduction of bilirubin such as from hemolysis or a resolving hematoma.",
"     </li>",
"     <li>",
"      Intrahepatic, which results from injury to hepatocytes or biliary epithelial cells and is due to a variety of causes such as hepatic ischemia, infection, and drug toxicity. All of these conditions may be more likely and clinically more severe in patients with preexisting liver disease.",
"     </li>",
"     <li>",
"      Posthepatic, which is due to obstruction of the extrahepatic biliary tree. Examples include a retained common bile duct stone or a direct biliary tract injury from upper abdominal surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These categories are not mutually exclusive since several factors are typically involved in causing postoperative jaundice. The clinical challenge is considering the multitude of causes in an effort to determine if intervention is possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREHEPATIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overproduction of unconjugated bilirubin can lead to jaundice. In the surgical setting, overproduction is usually due either to pathologic red blood cell breakdown (hemolysis) or erythrocyte breakdown after excessive bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\", section on 'Disorders associated with unconjugated hyperbilirubinemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemolysis can result from a transfusion reaction with certain medications or from mechanical effects due to shearing forces from exposure of red blood cells to intravascular devices. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=see_link\">",
"       \"Transfusion-associated immune and non immune-mediated hemolysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pain, fever, or chills around the time of red blood cell transfusion, coupled with dark urine, suggest a transfusion reaction as the cause of jaundice. Surgery can exacerbate hemolysis in patients with a preexisting hemolytic disease or a genetic predisposition to hemolysis (eg, sickle cell disease, hereditary spherocytosis, Gilbert's syndrome or glucose-6-phosphate dehydrogenase deficiency).",
"   </p>",
"   <p>",
"    Patients who have undergone surgery that exposes the blood flow to shearing forces (eg, cardiopulmonary bypass) can develop unconjugated hyperbilirubinemia due to mechanical red blood cell breakdown. Patients at greatest risk include young children, patients who have undergone extensive surgery with a long operative time, with preoperative heart failure and congestive hepatopathy, who have received prolonged hemodynamic support from a ventricular assist devices, intra-aortic balloon pump, or extracorporeal membrane oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9718/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythrocyte breakdown occurs in patients with internal bleeding, with subsequent resorption of the extravasated blood. Surgical trauma patients who have multiple injuries to muscle and soft tissue may be at particular risk. In other patients, a declining hematocrit may be a clue that jaundice is, at least in part, due to resorption of extravasated blood. Trauma patients with hemorrhage are also more likely to require blood transfusions, the breakdown of which can compound the jaundice seen in these patients. A review of case series and reports of jaundice in trauma patients showed that an overproduction of bilirubin due to hemolysis of transfused blood and breakdown of extravasated blood was the most common causative factor [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9718/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INTRAHEPATIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple insults in the perioperative period can lead to hepatocellular or canalicular dysfunction, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    , hypoxia, ischemia, drugs, newly acquired viral hepatitis, and sepsis.",
"   </p>",
"   <p>",
"    As noted above, liver dysfunction associated with perioperative insults may be more likely and clinically more severe in patients with preexisting liver disease. The clinical course depends upon the type of liver disease, its severity, the surgical procedure, and the type of anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=see_link\">",
"     \"Assessing surgical risk in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Underlying liver disease is not always recognized during preoperative evaluation. Thus, the possibility that underlying liver disease could be contributing to jaundice should be considered. The following will summarize some of the important causes of intrahepatic jaundice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver's complex vascular supply and high metabolic activity make it particularly vulnerable to circulatory disturbances. Ischemic hepatitis (also referred to as shock liver) refers to diffuse hepatic injury resulting from acute hypoperfusion. The hemodynamic insult is usually evident clinically before liver injury is recognized. Liver injury is typically recognized by a rapid rise in serum aminotransferase levels and an early massive rise in lactate dehydrogenase levels. Peak aminotransferase levels are usually reached one to three days after the hemodynamic insult and can be 25 to 250 times the upper limit of normal. Ischemic hepatitis is often accompanied by additional evidence of end-organ hypoperfusion, especially acute tubular necrosis of the kidney. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18568?source=see_link\">",
"     \"Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Drug-induced liver injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced liver injury (DILI) occurs with many drugs through a variety of mechanisms. Diagnosis can be difficult since the relationship between drug exposure and hepatic toxicity is not always clear, although supportive features are onset after beginning the drug and improvement after withdrawal. Although contemporary inhaled anesthetic agents uncommonly cause DILI, the degree of hepatic metabolisms correlates with the likelihood of a toxic reaction.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/63/17397?source=see_link\">",
"     Isoflurane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    undergo less hepatic metabolism than halothane or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/47/34548?source=see_link\">",
"     enflurane",
"    </a>",
"    and have the lowest risk of hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=see_link\">",
"     \"Assessing surgical risk in patients with liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Total parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     Total parenteral nutrition",
"    </a>",
"    (TPN) in critically ill patients has been associated with postoperative jaundice. In one study, 30 percent of patients receiving TPN had liver dysfunction as defined by biochemical evidence of cholestasis, liver necrosis, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9718/abstract/5\">",
"     5",
"    </a>",
"    ]. The use of excessive caloric amounts of TPN was noted to be a risk factor for liver dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Viral hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral hepatitis is an uncommon cause of postoperative jaundice, but can occur in the rare case of hospital outbreaks or in patients with preoperative exposure. The exacerbation of underlying chronic hepatitis B is also possible in patients with chronic infection, particularly in patients receiving immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POSTHEPATIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary obstruction related to either choledocholithiasis, biliary stricture, or bile leaks remains one of the most common cause of postoperative jaundice in patients undergoing abdominal surgery. Patients undergoing cholecystectomy, pancreatic surgery, or resections of tumors of the liver, gallbladder, or bile ducts are at particular risk.",
"   </p>",
"   <p>",
"    Surgery performed near the periphery of the bile ducts or gallbladder is associated with a risk of a bile leak or a stricture from dysfunctional biliary epithelial healing. A bile duct stricture can be due to surgical scarring or a narrow anastomosis. Bile leaks can occasionally present with jaundice and hyperbilirubinemia. In addition, patients undergoing cholecystectomy can retain stones in the bile ducts, causing obstruction. An unintended interruption or obstruction (eg, due to clips) in the bile duct can become clinically evident immediately or days after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bile leaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile leaks after upper abdominal surgery are most commonly due to injury to the bile ducts or the ducts of Luschka. The ducts of Luschka are small ducts occasionally present at the gallbladder fossa, originating from the right hepatic lobe and draining into the extrahepatic bile ducts. Most leaks are symptomatic and detected during the first week following surgery. Endoscopic therapy is successful in resolving approximately 90 percent of bile leaks after cholecystectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12152?source=see_link\">",
"     \"Endoscopic management of complications from laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Biliary strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of bile duct strictures after upper abdominal surgery depends on the location of the stricture, its severity, and the extent of delay until its recognition. Endoscopic and surgical approaches may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12152?source=see_link\">",
"     \"Endoscopic management of complications from laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acalculous cholecystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acalculous cholecystitis is an acute necroinflammatory disease of the gallbladder with a multifactorial pathogenesis. It can occur in any hospitalized patient, but most frequently it occurs in the critically ill. In the critically ill, who may be intubated and sedated, it may present with unexplained fever, leukocytosis, or vague abdominal discomfort. Abnormal liver biochemical tests may include hyperbilirubinemia, a mild increase in serum alkaline phosphatase and aminotransferase levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6742?source=see_link\">",
"     \"Acalculous cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MULTIFACTORIAL CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, postoperative jaundice is usually attributable to more than one cause. The following conditions are examples of causes that have several contributing mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Benign postoperative jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"benign postoperative jaundice\" was added to the medical lexicon to recognize the common occurrence of postoperative jaundice from a multifactorial etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9718/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Because the term encompasses a multitude of potentially contributing causes, it is not particularly helpful for identifying specific contributing causes that could potentially be amenable to intervention. Nevertheless, it still provides a useful description for patients with multiple possible causes of postoperative jaundice.",
"   </p>",
"   <p>",
"    The clinical features are overshadowed by those of the underlying condition. One review found that patients can develop severe jaundice with bilirubin levels as high as 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9718/abstract/8\">",
"     8",
"    </a>",
"    ]. Aminotransferase levels are usually less than five times the upper limit of normal, while the alkaline phosphatase levels are usually less than four times the upper limits of normal.",
"   </p>",
"   <p>",
"    The diagnosis remains one that depends upon excluding other causes, especially those that are amenable to intervention. A liver biopsy is rarely required, but when it has been performed, it has shown centrilobular congestion and cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9718/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the name, the course is not always benign. Prognosis depends mainly upon the underlying condition. In those who recover, jaundice will resolve gradually over weeks to months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe bacterial infections are commonly associated with cholestasis. Contributing causes include hypotension, hemolysis, medications, and bacterial endotoxins, which downregulate bilirubin and bile salt transporters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=see_link&amp;anchor=H22#H22\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\", section on 'Sepsis and low perfusion states'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one review of the literature, the total bilirubin was between 5 and 50",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    the alkaline phosphatase between two to three times the upper limit of normal, and the aminotransferases only mildly elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9718/abstract/8\">",
"     8",
"    </a>",
"    ]. Diagnosis is usually established by the clinical context and exclusion of other causes. A liver biopsy is generally not needed. In one review of biopsies obtained immediately after death in 15 patients with sepsis, the most common findings were centrilobular necrosis (80 percent), portal inflammation (73 percent), steatosis (73 percent), lobular inflammation (67 percent), hepatocellular apoptosis (67 percent), and",
"    <span class=\"nowrap\">",
"     cholangitis/cholangiolitis",
"    </span>",
"    (20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9718/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation is based upon a careful history, review of medications, perioperative course, and laboratory and imaging tests. The following checklist can help to guide evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Does the patient have known liver disease or risk factors for liver disease such as a history of alcoholism, intravenous drug use, a family history of liver disease?",
"     </li>",
"     <li>",
"      Are there any preoperative liver biochemical tests or imaging tests?",
"     </li>",
"     <li>",
"      Are there postoperative imaging tests?",
"     </li>",
"     <li>",
"      Did the patient receive transfusions?",
"     </li>",
"     <li>",
"      What was blood loss around surgery?",
"     </li>",
"     <li>",
"      Was this a trauma patient with significant soft-tissue bleeding?",
"     </li>",
"     <li>",
"      Did the patient receive a cardiopulmonary bypass or an intra-aortic balloon pump?",
"     </li>",
"     <li>",
"      Did the patient have upper abdominal surgery in which the bile duct could have been injured?",
"     </li>",
"     <li>",
"      Does the patient have heart failure now, or did the patient have heart failure preoperatively?",
"     </li>",
"     <li>",
"      Does the pattern of liver biochemical and other laboratory tests provide clues? For example, does the patient have evidence of hemolysis (eg, indirect hyperbilirubinemia, circulating spherocytic red cells, increased lactic dehydrogenase concentration, reduced serum haptoglobin, increased reticulocyte count or percentage)? Did the aminotransferases rise to high levels that could be supportive of ischemic hepatitis?",
"     </li>",
"     <li>",
"      What type of anesthesia did the patient receive?",
"     </li>",
"     <li>",
"      Did the patient receive drugs known to be associated with drug-induced liver disease?",
"     </li>",
"     <li>",
"      Was the patient septic?",
"     </li>",
"     <li>",
"      Is the patient febrile?",
"     </li>",
"     <li>",
"      Does the patient have stigmata of chronic liver disease (eg, spider angiomata, hepatosplenomegaly, ascites, and gynecomastia)?",
"     </li>",
"     <li>",
"      Does the patient have right upper quadrant pain?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further diagnostic evaluation should be based upon the history obtained above. As a general rule, we obtain a right upper quadrant ultrasound if imaging has not already been performed. A CT scan, MRI, or MRCP may also be needed, depending on the clinical context. We also obtain hepatitis serology (HBsAg, HBsAb, HBeAg, HCV ab or RNA, HAV IgM).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management and prognosis depend upon the underlying cause and the identification of causes for which specific intervention is possible. As noted above, patients with biliary tract obstruction from bile duct injury may require endoscopic, radiologic, or surgical intervention. Patients in whom drug-induced liver injury is suspected should receive alternative medications. Patients with acalculous cholecystitis should receive appropriate percutaneous or surgical therapy. In other patients, the clinical course largely depends upon the resolution of the underlying condition (such as sepsis). Jaundice will resolve in weeks to months after the underlying causes have resolved.",
"   </p>",
"   <p>",
"    Patients with severe cholestasis may have an elevated prothrombin time, which may respond to vitamin K. Prolonged cholestasis may lead to malabsorption of fats and other fat soluble vitamins, and thus nutritional evaluation may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/17/34066?source=see_link\">",
"       \"Patient information: Jaundice in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperative jaundice is defined as the presence of bilirubin elevation with or without clinical icterus appearing in the period following surgery.",
"     </li>",
"     <li>",
"      We have found it useful conceptually to subdivide postoperative jaundice into three categories: prehepatic, intrahepatic, and posthepatic. However, the cause of jaundice is usually multifactorial. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation is based upon a careful history, review of medications, perioperative course, and laboratory and imaging tests. The checklist described above can provide a framework for evaluating the patient. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management and prognosis depend upon the underlying cause and the identification of causes for which specific intervention is possible. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9718/abstract/1\">",
"      Mastoraki A, Karatzis E, Mastoraki S, et al. Postoperative jaundice after cardiac surgery. Hepatobiliary Pancreat Dis Int 2007; 6:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9718/abstract/2\">",
"      An Y, Xiao YB, Zhong QJ. Hyperbilirubinemia after extracorporeal circulation surgery: a recent and prospective study. World J Gastroenterol 2006; 12:6722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9718/abstract/3\">",
"      Vercaemst L. Hemolysis in cardiac surgery patients undergoing cardiopulmonary bypass: a review in search of a treatment algorithm. J Extra Corpor Technol 2008; 40:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9718/abstract/4\">",
"      Labori KJ, Raeder MG. Diagnostic approach to the patient with jaundice following trauma. Scand J Surg 2004; 93:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9718/abstract/5\">",
"      Grau T, Bonet A, Rubio M, et al. Liver dysfunction associated with artificial nutrition in critically ill patients. Crit Care 2007; 11:R10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9718/abstract/6\">",
"      SCHMID M, HEFTI ML, SENNING A. [BENIGN POSTOPERATIVE ICTERUS]. Helv Med Acta 1964; 31:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9718/abstract/7\">",
"      Kantrowitz PA, Jones WA, Greenberger NJ, Isselbacher KJ. Severe postoperative hyperbilirubinemia simulating obstructive jaundice. N Engl J Med 1967; 276:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9718/abstract/8\">",
"      Faust TW, Reddy KR. Postoperative jaundice. Clin Liver Dis 2004; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9718/abstract/9\">",
"      Hartley S, Scott AJ, Spence M. Benign postoperative jaundice complicating severe trauma. N Z Med J 1977; 86:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9718/abstract/10\">",
"      Koskinas J, Gomatos IP, Tiniakos DG, et al. Liver histology in ICU patients dying from sepsis: a clinico-pathological study. World J Gastroenterol 2008; 14:1389.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3604 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9718=[""].join("\n");
var outline_f9_31_9718=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREHEPATIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INTRAHEPATIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Total parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Viral hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POSTHEPATIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bile leaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Biliary strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acalculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MULTIFACTORIAL CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Benign postoperative jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6742?source=related_link\">",
"      Acalculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=related_link\">",
"      Assessing surgical risk in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=related_link\">",
"      Bilirubin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=related_link\">",
"      Complications of laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12152?source=related_link\">",
"      Endoscopic management of complications from laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18568?source=related_link\">",
"      Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/17/34066?source=related_link\">",
"      Patient information: Jaundice in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=related_link\">",
"      Transfusion-associated immune and non immune-mediated hemolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_31_9719="ECG digoxin toxicity in AF 3";
var content_f9_31_9719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1127px;\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Single-lead electrocardiogram (ECG) showing atrial fibrillation with further accelerated junctional pacemaker",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 131px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 4 electrocardiograms in this sequence demonstrate increasing severity of digoxin toxicity in a patient with atrial fibrillation.",
"    <br>",
"     <br>",
"      In this strip, the R-R intervals remain constant with&nbsp;further acceleration of the junctional pacemaker to a rate of 142 beats per minute.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       The four electrocardiograms are adapted from Childers, R, Med Clin North Am 1976; 60:3.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9719=[""].join("\n");
var outline_f9_31_9719=null;
var title_f9_31_9720="Hyperimmunoglobulin-D syndrome: Pathophysiology";
var content_f9_31_9720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyperimmunoglobulin-D syndrome: Pathophysiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9720/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9720/contributors\">",
"     Yoram C Padeh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9720/contributors\">",
"     Arye Rubinstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9720/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9720/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9720/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9720/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/31/9720/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyperimmunoglobulin-D syndrome (HIDS) is a rare genetic disorder characterized by recurrent febrile episodes typically associated with lymphadenopathy, abdominal pain, and an elevated serum polyclonal IgD level (MIM #260920). The syndrome can be further categorized into classical and variant forms. The classical form includes over 75 percent of cases whose genetic defect is known. The variant form has similar clinical manifestations, although its genetic basis has not yet been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the genetics and pathophysiology of HIDS. The clinical manifestations, diagnosis, and management of this disorder are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23670?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic HIDS is caused by mutant mevalonate kinase (MVK) genes and is inherited as an autosomal recessive trait. Most patients are compound heterozygous for two different defects in the MVK gene. However, some patients may be homozygous for the same defect on both alleles.",
"   </p>",
"   <p>",
"    Various types of mutations have been identified, including missense, nonsense, frame-shift, and short interstitial deletions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Haplotype and geographic analysis suggests a founder effect beginning in The Netherlands [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with similar clinical features but lacking mutant MVK genes are referred to as having variant HIDS. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Variant HIDS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mevalonate kinase gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously noted, the classic form of HIDS is caused by defects in the mevalonate kinase (MVK) gene. The association between MVK gene mutations and HIDS was identified by two different groups of investigators using two different methods. One group used linkage analysis to identify the gene [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/5\">",
"     5",
"    </a>",
"    ], while the discovery of elevated levels of mevalonic acid in the urine of patients during febrile episodes, and reduced MK enzyme activity in four unrelated HIDS patients, led another group to focus on MVK as a candidate gene [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MVK gene is located on long arm of chromosome 12 (12q24) and is 22 kb long. It consists of 11 exons of 46 to 837 base pairs and 10 introns of 379 to 4.2 kb [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/7\">",
"     7",
"    </a>",
"    ]. The gene product, mevalonate kinase (MK), is a 397 amino acid enzyme in the cholesterol synthesis pathway. This pathway is responsible for the synthesis of sterol products such as cholesterol and its derivatives, as well as non-sterol isoprenoids, including: prenylated proteins, heme A, dolichol, and ubiquinone-10 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. MK is one enzyme downstream of the highly regulated HMG-CoA reductase (HMGR) enzyme (",
"    <a class=\"graphic graphic_algorithm graphicRef66072 \" href=\"UTD.htm?29/52/30542\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mevalonate kinase enzyme",
"    </span>",
"    &nbsp;&mdash;&nbsp;MK is a cytosolic protein that is localized to the peroxisome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Only one isoform has been shown to exist [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/10\">",
"     10",
"    </a>",
"    ]. It is a member of the GHMP kinase family of proteins, which includes",
"    <strong>",
"     g",
"    </strong>",
"    alactokinase,",
"    <strong>",
"     h",
"    </strong>",
"    omoserine kinase,",
"    <strong>",
"     m",
"    </strong>",
"    evalonate kinase, and",
"    <strong>",
"     p",
"    </strong>",
"    hosphomevalonate kinase.",
"   </p>",
"   <p>",
"    These kinases share three highly conserved glycine-rich motifs implicated in the binding of adenosine triphosphate (ATP). Motif I is located at the N-terminus and forms part of the \"roof\" of the enzyme active site [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Motif II is termed a \"phosphate binding loop\" and functions to securely position ATP. Motif III is in close contact with motif II and helps to stabilize the \"phosphate binding loop\" [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Structural analysis through crystallization structures of rat MK have demonstrated the protein to exist as a homodimer. In each monomer (",
"    <a class=\"graphic graphic_figure graphicRef64989 \" href=\"UTD.htm?13/63/14325\">",
"     figure 1",
"    </a>",
"    ) two pockets are formed in the tertiary structure, one for an ATP-magnesium moiety and another for the mevalonic acid molecule. These pockets bring the two molecules in close proximity to each other and to enzymatically active amino acid side chains, to the exclusion of solvent (",
"    <a class=\"graphic graphic_figure graphicRef67140 \" href=\"UTD.htm?16/22/16741\">",
"     figure 2",
"    </a>",
"    ), catalyzing the phosphorylation of mevalonic acid (",
"    <a class=\"graphic graphic_figure graphicRef79953 \" href=\"UTD.htm?34/46/35553\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic mutations in HIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, a number of mutations have been described in patients with HIDS. There is some evidence for a correlation between specific mutations in the MVK gene and the clinical phenotype.",
"   </p>",
"   <p>",
"    Compound heterozygous MVK mutations in HIDS patients usually consist of one allele with a mutation, such as a H20P, I268T, or A334T mutation, which when present in a homozygous state cause mevalonic aciduria (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Mevalonic aciduria'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/15\">",
"     15",
"    </a>",
"    ]. In patients with HIDS, the other allele has a mutation that is not typical for mevalonic aciduria.",
"   </p>",
"   <p>",
"    The V377I mutation is frequently the second mutation in patients with HIDS (in from 52 to over 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/7,16,17\">",
"     7,16,17",
"    </a>",
"    ]. In HIDS patients without the V377I mutation, another mutation probably causes a similar enzymatic defect leading to 1 to 12 percent residual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/2\">",
"     2",
"    </a>",
"    ]. The conclusion is that the V377I mutation is somehow responsible for the HIDS phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/7,16,18\">",
"     7,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 15-year-old Japanese girl diagnosed with HIDS who was homozygous for the G326R mutation was described in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/19\">",
"     19",
"    </a>",
"    ]. While compound heterozygous HIDS patients with this mutation (in addition to V377I) are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/17\">",
"     17",
"    </a>",
"    ], homozygosity for G326R was previously described as causing mevalonic aciduria (MA) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/20\">",
"     20",
"    </a>",
"    ]. It is possible that the enzyme deficiency is mild for patients who present with MA and severe for those who present with clinical features consistent with HIDS in such homozygous patients, leading to a diagnosis based upon the clinical impression at the time. A similar case was described in a 20-month-old Turkish boy diagnosed with HIDS who was homozygous for the T322S mutation and heterozygous for the E148Q FMF mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The common V377I mutation felt to be responsible for the HIDS phenotype has been predicted not to cause a significant structural change in the MVK enzyme that would affect enzymatic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the folding or stability of the MVK protein, specifically at body temperature may be altered. This hypothesis was studied in fibroblast cell lines from patients with mevalonic aciduria, HIDS, and control subjects at three temperatures: 30, 37, and 39&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/18\">",
"     18",
"    </a>",
"    ]. The activity of MK in cell lines from those with mevalonic aciduria did not change significantly with temperature, while the activity of MK from control cells decreased with increasing temperature. HIDS cell lines had the same temperature-activity relationship as controls, but much more pronounced. MK produced at 30&ordm;C by HIDS cells had activity that was similar to controls and the decrement in activity that occurred at the highest temperature was also similar to that derived from controls cells.",
"   </p>",
"   <p>",
"    Increased enzyme activity and increased MK protein in cultured fibroblasts are closely correlated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/22\">",
"     22",
"    </a>",
"    ]. Taken together these data suggest that the V377I mutation, and others like it, probably prevent appropriate folding of newly-formed MK proteins at body temperature (37&ordm;C), thereby causing decreased in vivo enzyme activity. Finally, HMGR activity was found to be increased at increasing temperatures in cells from patients with mevalonic aciduria more than HIDS cells, but did not increase in control cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mevalonic aciduria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mevalonic aciduria is also associated with mutations in the MVK gene. The phenotype of mevalonic aciduria is, however, more severe and often lethal. Although infants with mevalonic aciduria experience febrile episodes, they present with severe intellectual disability (mental retardation), ataxia, failure to thrive, myopathy, and cataracts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/23\">",
"     23",
"    </a>",
"    ]. Very little or no MK enzyme activity is present in affected children; &lt;0.5 percent activity compared to normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Patients are often homozygous for mutations, such as H20P, I268T, and A334T [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/15\">",
"     15",
"    </a>",
"    ]. Structural analysis suggests that these mutations interfere with the active sites of the MVK enzyme thereby significantly reducing or inhibiting its activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some suggest that mevalonic aciduria and HIDS are simply two points on a spectrum of disease, which has been termed mevalonate kinase deficiency (MKD) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Support for this view includes the observation that IgD may not be elevated in all cases of HIDS or may be elevated in patients with mevalonic aciduria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Other authors disagree and maintain that HIDS and mevalonic aciduria are clinically distinct diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was estimated that the incidence of HIDS should be 1:5000 to 1:50,000 in the general population, however the observed incidence is much lower, suggesting decreased penetrance of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/30\">",
"     30",
"    </a>",
"    ]. Autosomal recessive homozygous genotypes, especially of the V377I mutation, are encountered with less frequency than expected, assuming these mutations to be in Hardy-Weinberg equilibrium within the population, suggesting incomplete penetrance of this genotype specifically [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/4,15\">",
"     4,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homozygous V377I mutations would theoretically allow for double the enzymatic activity found in compound heterozygous HIDS patients with a V377I and a nonfunctional allele (eg, H20P, I268T, or A334T mutations). A range of 1 to 12 percent of residual enzyme activity would be expected. This configuration may or may not result in sufficient reduction of enzymatic activity to yield the HIDS phenotype, thus contributing to the observed incomplete penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/15\">",
"     15",
"    </a>",
"    ]. Perhaps other minor mutations are present in downstream enzymes in such homozygous patients who demonstrate the HIDS phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overlap syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations found in other rare periodic fever syndromes have been identified in some HIDS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/25,32\">",
"     25,32",
"    </a>",
"    ]. These \"overlap syndromes\" may account for clinical features that are unusual in HIDS patients, such as amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. One patient with HIDS and systemic amyloidosis was homozygous for the",
"    <span class=\"nowrap\">",
"     alpha/alpha",
"    </span>",
"    genotype of the serum amyloid A 1 (SAA1) gene and was also a compound heterozygote for HIDS mutations (H20P and V250I) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/35\">",
"     35",
"    </a>",
"    ]. Such coincidental mutations may also account for atypical responses to medical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/36\">",
"     36",
"    </a>",
"    ]. Further genetic and clinical studies on patients with hereditary periodic fever syndromes are required to support the concept of overlap syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A successful explanatory model of HIDS pathophysiology needs to account for the periodicity of fevers, the frequent presence of increased serum levels of IgD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IgA, and the HIDS phenotype in patients with no identifiable mutations in the MVK gene.",
"   </p>",
"   <p>",
"    Although reduced MK enzyme activity that results from mutations in the MVK gene is responsible for many cases of HIDS, the pathophysiologic mechanisms through which the genetic defect causes the HIDS phenotype remains unknown. Several theories regarding the primary etiologic factor or factors triggering febrile episodes have been proposed, but none has been proven or validated. There is some support for the suggestion that HIDS mutations cause temperature-dependent instability in the MK enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/8,18\">",
"     8,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serum IgD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Is elevated IgD part of the autoinflammatory process or an epiphenomenon? An early hypothesis suggested that circulating IgD immune complexes in a type III Gell and Coombs hypersensitivity reaction was responsible for the physical manifestations of the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], although no consistent supporting evidence was found [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some in vitro experimental data suggest that IgD may be proinflammatory. This effect was illustrated when peripheral blood mononuclear cells (PBMCs) from normal patients were exposed in vitro to IgD purified from an HIDS patient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/40\">",
"     40",
"    </a>",
"    ]. Large quantities of Interleukin-1 (IL-1), IL-6, IL-1 receptor antagonist (IL-1ra), and tumor necrosis factor (TNF)-alpha were detected. IgD also enhanced cytokine production in response to lipopolysaccharide (LPS), a potent inducer of inflammatory cytokines.",
"   </p>",
"   <p>",
"    The degree of O-glycosylation of IgD and IgA1 may alter the inflammatory nature of these immunoglobulins. The T-cell IgD receptor is a lectin that has a binding affinity for the O-glycans of IgD and IgA1. Patients with HIDS have increased O-galactosylation of IgD and decreased O-sialylation of both IgD and IgA1 compared with normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/41\">",
"     41",
"    </a>",
"    ]. The authors hypothesize that this may have a significant effect on basal immunoglobulin synthesis as well as myeloid cytokine release. However, serum IgD and its O-galactosylation are elevated between, as well as during, attacks. In addition, IgD levels do not appear to correlate with the frequency or severity of attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mevalonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Does elevated mevalonate itself cause fever or promote inflammation? Both HIDS and mevalonic aciduria patients demonstrate mevalonic aciduria. However, in those with HIDS the increased excretion of mevalonic acid is transient and only occurs during febrile episodes. A direct correlation with the amount of mevalonate production seems unlikely. As an example, treatment of two patients with the HMGR-inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    , which should have reduced mevalonate synthesis, resulted in severe crises in both cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supplying metabolic products downstream of mevalonate may have a favorable antiinflammatory effect. This was illustrated in an in vitro study using peripheral blood mononuclear cells (PBMC) from HIDS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/43\">",
"     43",
"    </a>",
"    ]. Production of IL-1 beta was increased relative to that from PBMC of healthy controls. A further increase in IL-1 beta was noted following blockade of HMGR, using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    , but was partially reversed by adding farnesol (FOH) and geranylgeraniol (GGOH), two downstream intermediates in the cholesterol synthetic pathway. FOH decreased IL-1 beta production by 62 percent in cells from HIDS patients. Adding mevalonic acid caused a smaller effect but also decreased, rather than increased, IL-1 beta release.",
"   </p>",
"   <p>",
"    Another in vitro study compared fibroblast cell cultures from patients with HIDS, mevalonic aciduria, and control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/44\">",
"     44",
"    </a>",
"    ]. Production of pathway end-products was most decreased by the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    in cell lines from those with mevalonic aciduria, followed by HIDS, and was least affected in controls. Cell lines from patients with mevalonic aciduria and HIDS were found to be more sensitive to non-sterol feedback inhibition than to sterol control. FOH was found to increase HMGR degradation, while GGOH was found to decrease HMGR efficiency. Elevated mevalonic acid levels in both mevalonic aciduria and HIDS cell lines produced by elevated HMGR activity was found to be important for driving the continued production of pathway end-products.",
"   </p>",
"   <p>",
"    These studies together suggest that elevated mevalonic acid levels more likely help to prevent attacks than to promote them [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sterol synthesis pathway products",
"    </span>",
"    &nbsp;&mdash;&nbsp;A deficiency of cholesterol or its derivative seems unlikely to be important in causing fever or other symptoms of HIDS. Patients with HIDS appear to have normal cholesterol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition the in vitro study cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/44\">",
"     44",
"    </a>",
"    ] noted continued cholesterol synthesis in cultured cell lines from HIDS subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Non-sterol synthesis pathway products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cholesterol biosynthetic pathway intermediates, such as polyisoprenyl phosphates (PIPP), presqualene diphosphate (PSDP), and presqualene monophosphate (PSMP) may serve as potent signaling molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/46\">",
"     46",
"    </a>",
"    ]. The non-sterol end-products, the isoprenoids, also play important cellular roles, including as components of prenylated proteins (cytokine signaling, cell cycling, cell development), heme A (electron transport), dolichol (glycoprotein synthesis), ubiquinone-10 (electron transport, antioxidant), and isopentenyl tRNAs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Some small G-proteins, which are involved in cellular signaling, are prenylated proteins.",
"   </p>",
"   <p>",
"    One such G-protein of the Rho family, Rac-1, plays a critical role in caspase-1 activation through inflammasome oligomerization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/44,47\">",
"     44,47",
"    </a>",
"    ]. The NLRP3 inflammasome is linked to familial Mediterranean fever (FMF) and cryopyrin-associated periodic syndromes (CAPS), but has not yet been linked specifically to Rac-1 activation of caspase-1. Rac-1 has increased activity in the presence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Other studies have shown that inhibition of the mevalonate pathway with a geranylgeranyl-transferase inhibitor and with simvastatin (an HMG-CoA-reductase inhibitor) leads to a caspase-1-dependent release of IL-1 beta and IL-18 by activated monocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/48,50\">",
"     48,50",
"    </a>",
"    ]. Farnesyl transferase inhibitors lack this effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/48\">",
"     48",
"    </a>",
"    ]. Additionally, dermal fibroblasts cultured from healthy donors increased production of IL-1 beta to levels matching that of dermal fibroblasts cultured from mevalonate kinase deficient (MKD) donors when exposed to simvastatin. Combining simvastatin with mevalonate reduces IL-1 beta production in fibroblasts from healthy donors, but not in those from MKD donors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disruption of cellular signaling caused by decreased production of non-sterol pathway products, cytokine derangements, and an inflammatory process seem plausible results of partial MK enzyme deficiency. This does not, however, address the limited periodic nature of HIDS attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Variant HIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in downstream enzymes have been proposed to account for variant HIDS given that the phenotypes are essentially the same [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/52\">",
"     52",
"    </a>",
"    ]. Such mutations would also create a lack of non-sterol isoprenoids, one of the above-mentioned mechanisms proposed to cause febrile episodes in classic HIDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Secondary mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the primary cause, cytokine activation is thought to contribute to the symptoms experienced by patients during febrile episodes. Elevated circulating IL-6 and TNF-alpha levels are present during febrile episodes when compared to asymptomatic intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/53\">",
"     53",
"    </a>",
"    ]. IL-6 levels correlated significantly with C-reactive protein (CRP) levels. Antiinflammatory molecules, such as IL-1-receptor-antagonist (IL-1Ra) and soluble TNF receptor superfamily 1A (sTNFRSF1A: sTNFr p55 and p75) were found to be elevated as well during attacks. Inflammatory IL-1 alpha, IL-1 beta and the antiinflammatory cytokine, IL-10, levels were not elevated during febrile episodes.",
"   </p>",
"   <p>",
"    Persistently elevated alpha1-acid glycoprotein (AGP) in HIDS patients compared to normal controls points to a continued inflammatory state even between attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/54\">",
"     54",
"    </a>",
"    ]. Finally, increased urinary neopterin levels in HIDS patients during febrile episodes, which normalize between attacks, represent products of monocytes and macrophages that have been stimulated by interferon-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     A PLAUSIBLE EXPLANATORY MODEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;One explanatory model begins with triggering events that cause transient elevations in body temperature. Temperature sensitivity of the MK enzyme leads to the decreased production of mevalonate 5-phosphate and downstream non-sterol isoprenoids, particularly those with high turnover (ubiquinone-10 in patients with mevalonic aciduria, antiinflammatory isoprenoids in HIDS patients) promoting a proinflammatory phenotype with more fever and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/8,18\">",
"     8,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In HIDS patients, this cascade leads to increased HMGR activity which increases mevalonate levels and drives production of non-sterol end-products despite persistently decreased MK enzyme activity at higher temperatures. Eventually homeostasis is restored and the febrile episode ends.",
"   </p>",
"   <p>",
"    In comparison, patients with mevalonic aciduria have such low MK enzyme activity at baseline that HMGR activity is already at maximum and mevalonate levels are as well, so no further increase in the production of pathway end-products can be achieved.",
"   </p>",
"   <p>",
"    This theory explains why events such as vaccinations, minor trauma, surgery, or stress can trigger an attack in HIDS patients, and is in general agreement with the observed phenotype and the above in vitro data. More clinical and molecular studies are required, though, before this theory can become widely accepted.",
"   </p>",
"   <p>",
"    It has been suggested that the defect in variant HIDS may be in a downstream enzyme as some patients have been found to have normal MK activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1895696\">",
"    <span class=\"h1\">",
"     MOUSE MODEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first mouse model of HIDS was created by deleting a single MVK allele. These mice exhibit similar biochemical features as humans with HIDS, including elevated IgD and IgA. Further investigation with this mouse model may yield a better understanding of HIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9720/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hyperimmunoglobulin-D syndrome (HIDS) is characterized by febrile episodes that are typically associated with lymphadenopathy, abdominal pain, and an elevated serum polyclonal IgD level. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=see_link\">",
"       \"Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mutations of the mevalonate kinase (MVK) gene are responsible for the autosomal recessive pattern of inheritance seen in many cases of the hyperimmunoglobulin-D syndrome (classic HIDS). Impaired folding of the mevalonate kinase protein at body temperature may play a role in decreased enzyme activity. A similar phenotype may occur in the absence of mutations of the MVK gene and is referred to as variant HIDS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mevalonate kinase gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mevalonic aciduria, another genetic disorder associated with the MVK gene, has a more severe phenotype, more profound loss of mevalonate kinase enzymatic activity. It is frequently lethal in infancy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mevalonic aciduria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathophysiology of HIDS and mevalonic aciduria are incompletely understood. Although IgD levels are typically elevated in HIDS, it seems unlikely that elevated serum levels of IgD are responsible for the periodic fevers and other symptoms of HIDS. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Serum IgD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neither the increased production of mevalonate nor the increased excretion of mevalonic acid appears to be the proximate cause of the inflammatory phenotype. Attempts to decrease mevalonate production using statin drugs in patients with HIDS have led to worsening of disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mevalonate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased availability of non-sterol biosynthetic pathway intermediates (which may have antiinflammatory properties) has been postulated to be of pathophysiologic importance. In vitro studies suggest that supplying exogenous precursors (farnesol and geranylgeraniol) for downstream products may reduce the production of proinflammatory cytokines from cultured cells from patients with HIDS. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Non-sterol synthesis pathway products'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'A plausible explanatory model'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/1\">",
"      Simon A, Cuisset L, Vincent MF, et al. Molecular analysis of the mevalonate kinase gene in a cohort of patients with the hyper-igd and periodic fever syndrome: its application as a diagnostic tool. Ann Intern Med 2001; 135:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/2\">",
"      Hospach T, Lohse P, Heilbronner H, et al. Pseudodominant inheritance of the hyperimmunoglobulinemia D with periodic fever syndrome in a mother and her two monozygotic twins. Arthritis Rheum 2005; 52:3606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/3\">",
"      Frenkel J, Kuis W. Overt and occult rheumatic diseases: the child with chronic fever. Best Pract Res Clin Rheumatol 2002; 16:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/4\">",
"      Simon A, Mariman EC, van der Meer JW, Drenth JP. A founder effect in the hyperimmunoglobulinemia D and periodic fever syndrome. Am J Med 2003; 114:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/5\">",
"      Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999; 22:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/6\">",
"      Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999; 22:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/7\">",
"      Houten SM, Koster J, Romeijn GJ, et al. Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome. Eur J Hum Genet 2001; 9:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/8\">",
"      Houten SM, Frenkel J, Waterham HR. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci 2003; 60:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/9\">",
"      Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/10\">",
"      Biardi L, Sreedhar A, Zokaei A, et al. Mevalonate kinase is predominantly localized in peroxisomes and is defective in patients with peroxisome deficiency disorders. J Biol Chem 1994; 269:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/11\">",
"      Wanders RJ, Romeijn GJ. Differential deficiency of mevalonate kinase and phosphomevalonate kinase in patients with distinct defects in peroxisome biogenesis: evidence for a major role of peroxisomes in cholesterol biosynthesis. Biochem Biophys Res Commun 1998; 247:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/12\">",
"      Chu X, Li D. Expression, purification, and characterization of His20 mutants of rat mevalonate kinase. Protein Expr Purif 2003; 32:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/13\">",
"      Chu X, Li D. Cloning, expression, and purification of His-tagged rat mevalonate kinase. Protein Expr Purif 2003; 27:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/14\">",
"      Fu Z, Wang M, Potter D, et al. The structure of a binary complex between a mammalian mevalonate kinase and ATP: insights into the reaction mechanism and human inherited disease. J Biol Chem 2002; 277:18134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/15\">",
"      Houten SM, van Woerden CS, Wijburg FA, et al. Carrier frequency of the V377I (1129G&gt;A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. Eur J Hum Genet 2003; 11:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/16\">",
"      Houten SM, Frenkel J, Kuis W, et al. Molecular basis of classical mevalonic aciduria and the hyperimmunoglobulinaemia D and periodic fever syndrome: high frequency of 3 mutations in the mevalonate kinase gene. J Inherit Metab Dis 2000; 23:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/17\">",
"      Cuisset L, Drenth JP, Simon A, et al. Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur J Hum Genet 2001; 9:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/18\">",
"      Houten SM, Frenkel J, Rijkers GT, et al. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002; 11:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/19\">",
"      Naruto T, Nakagishi Y, Mori M, et al. Hyper-IgD syndrome with novel mutation in a Japanese girl. Mod Rheumatol 2009; 19:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/20\">",
"      Neven B, Valayannopoulos V, Quartier P, et al. Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med 2007; 356:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/21\">",
"      Topalolu R, Ayaz NA, Waterham HR, et al. Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up. Clin Rheumatol 2008; 27:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/22\">",
"      Mandey SH, Schneiders MS, Koster J, Waterham HR. Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Hum Mutat 2006; 27:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/23\">",
"      Hoffmann GF, Charpentier C, Mayatepek E, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 1993; 91:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/24\">",
"      Tsimaratos M, Kone-Paut I, Divry P, et al. Mevalonic aciduria and hyper-IgD syndrome: two sides of the same coin? J Inherit Metab Dis 2001; 24:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/25\">",
"      Stojanov S, Lohse P, Lohse P, et al. Molecular analysis of the MVK and TNFRSF1A genes in patients with a clinical presentation typical of the hyperimmunoglobulinemia D with periodic fever syndrome: a low-penetrance TNFRSF1A variant in a heterozygous MVK carrier possibly influences the phenotype of hyperimmunoglobulinemia D with periodic fever syndrome or vice versa. Arthritis Rheum 2004; 50:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/26\">",
"      Gibson KM, Hoffmann GF, Sweetman L, Buckingham B. Mevalonate kinase deficiency in a dizygotic twin with mild mevalonic aciduria. J Inherit Metab Dis 1997; 20:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/27\">",
"      Prietsch V, Mayatepek E, Krastel H, et al. Mevalonate kinase deficiency: enlarging the clinical and biochemical spectrum. Pediatrics 2003; 111:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/28\">",
"      D'Osualdo A, Picco P, Caroli F, et al. MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever. Eur J Hum Genet 2005; 13:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/29\">",
"      Poll-The BT, Frenkel J, Houten SM, et al. Mevalonic aciduria in 12 unrelated patients with hyperimmunoglobulinaemia D and periodic fever syndrome. J Inherit Metab Dis 2000; 23:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/30\">",
"      Grose C. Periodic fever in children with hyperimmunoglobulinemia D and mevalonate kinase mutations. Pediatr Infect Dis J 2005; 24:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/31\">",
"      Hammoudeh M. Hyperimmunoglobulinemia D syndrome in an Arab child. Clin Rheumatol 2005; 24:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/32\">",
"      Hoffmann F, Lohse P, Stojanov S, et al. Identification of a novel mevalonate kinase gene mutation in combination with the common MVK V377I substitution and the low-penetrance TNFRSF1A R92Q mutation. Eur J Hum Genet 2005; 13:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/33\">",
"      Obici L, Manno C, Muda AO, et al. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2004; 50:2966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/34\">",
"      van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/35\">",
"      Siewert R, Ferber J, Horstmann RD, et al. Hereditary periodic fever with systemic amyloidosis: is hyper-IgD syndrome really a benign disease? Am J Kidney Dis 2006; 48:e41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/36\">",
"      Arkwright PD, McDermott MF, Houten SM, et al. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 2002; 130:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/37\">",
"      Hiemstra I, Vossen JM, van der Meer JW, et al. Clinical and immunological studies in patients with an increased serum IgD level. J Clin Immunol 1989; 9:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/38\">",
"      Boom BW, Daha MR, Vermeer BJ, van der Meer JW. IgD immune complex vasculitis in a patient with hyperimmunoglobulinemia D and periodic fever. Arch Dermatol 1990; 126:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/39\">",
"      Drenth JP, Powell RJ. Hyperimmunoglobulinaemia D syndrome. Lancet 1995; 345:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/40\">",
"      Drenth JP, G&ouml;ertz J, Daha MR, van der Meer JW. Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells. Immunology 1996; 88:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/41\">",
"      de Wolff JF, Dickinson SJ, Smith AC, et al. Abnormal IgD and IgA1 O-glycosylation in hyperimmunoglobulinaemia D and periodic fever syndrome. Clin Exp Med 2009; 9:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/42\">",
"      Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994; 73:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/43\">",
"      Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2002; 46:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/44\">",
"      Houten SM, Schneiders MS, Wanders RJ, Waterham HR. Regulation of isoprenoid/cholesterol biosynthesis in cells from mevalonate kinase-deficient patients. J Biol Chem 2003; 278:5736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/45\">",
"      Simon A, Bijzet J, Voorbij HA, et al. Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. J Intern Med 2004; 256:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/46\">",
"      Levy BD, Petasis NA, Serhan CN. Polyisoprenyl phosphates in intracellular signalling. Nature 1997; 389:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/47\">",
"      Mandey SH, Kuijk LM, Frenkel J, Waterham HR. A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 2006; 54:3690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/48\">",
"      Massonnet B, Normand S, Moschitz R, et al. Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes. Eur Cytokine Netw 2009; 20:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/49\">",
"      Kuijk LM, Beekman JM, Koster J, et al. HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 2008; 112:3563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/50\">",
"      Kuijk LM, Mandey SH, Schellens I, et al. Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1. Mol Immunol 2008; 45:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/51\">",
"      Normand S, Massonnet B, Delwail A, et al. Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation. Eur Cytokine Netw 2009; 20:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/52\">",
"      Frenkel J, Houten SM, Waterham HR, et al. Clinical and molecular variability in childhood periodic fever with hyperimmunoglobulinaemia D. Rheumatology (Oxford) 2001; 40:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/53\">",
"      Drenth JP, van Deuren M, van der Ven-Jongekrijg J, et al. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 1995; 85:3586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/54\">",
"      Havenaar EC, Drenth JP, van Ommen EC, et al. Elevated serum level and altered glycosylation of alpha 1-acid glycoprotein in hyperimmunoglobulinemia D and periodic fever syndrome: evidence for persistent inflammation. Clin Immunol Immunopathol 1995; 76:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/55\">",
"      Drenth JP, Powell RJ, Brown NS, Van der Meer JW. Interferon-gamma and urine neopterin in attacks of the hyperimmunoglobulinaemia D and periodic fever syndrome. Eur J Clin Invest 1995; 25:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9720/abstract/56\">",
"      Hager EJ, Tse HM, Piganelli JD, et al. Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome. J Inherit Metab Dis 2007; 30:888.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5956 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-3918385851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9720=[""].join("\n");
var outline_f9_31_9720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mevalonate kinase gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mevalonate kinase enzyme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic mutations in HIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mevalonic aciduria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overlap syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serum IgD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mevalonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sterol synthesis pathway products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Non-sterol synthesis pathway products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Variant HIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Secondary mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      A PLAUSIBLE EXPLANATORY MODEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1895696\">",
"      MOUSE MODEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5956\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5956|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/52/30542\" title=\"algorithm 1\">",
"      Cholesterol synthesis pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5956|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/63/14325\" title=\"figure 1\">",
"      Structure mevalonate kinase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/22/16741\" title=\"figure 2\">",
"      Mevalonate kinase active site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/46/35553\" title=\"figure 3\">",
"      Mevalonate kinase mechanism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23670?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_31_9721="Evaluation of premenopausal women with hirsutism";
var content_f9_31_9721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of premenopausal women with hirsutism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9721/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9721/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9721/contributors\">",
"     David A Ehrmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9721/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9721/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9721/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9721/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/31/9721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H325960\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hirsutism, defined as excessive male-pattern hair growth, affects between 5 and 10 percent of women of reproductive age. It may be the initial, and possibly only, sign of an underlying androgen disorder, the cutaneous manifestations of which may also include acne and male-pattern balding (androgenetic alopecia). The most common cause of hirsutism is polycystic ovary syndrome (PCOS). In some cases, hirsutism is mild and requires only reassurance and local (nonsystemic) therapy, while in others it causes significant psychological distress and requires more extensive therapy.",
"   </p>",
"   <p>",
"    The evaluation and laboratory testing of hirsutism will be discussed here, while its pathogenesis, causes, and treatment are discussed elsewhere (",
"    <a class=\"graphic graphic_table graphicRef65205 \" href=\"UTD.htm?25/33/26139\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=see_link\">",
"     \"Pathogenesis and causes of hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H253046823\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hirsutism is a clinical diagnosis, defined by the presence of excess terminal hair growth (dark, coarse hairs) in androgen-sensitive areas (eg, upper lip, chin, midsternum, upper abdomen, back, and buttocks) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It affects approximately 5 to 10 percent of women, is associated with significant emotional distress [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/3-5\">",
"     3-5",
"    </a>",
"    ], and is usually an indication of an underlying endocrine disorder (most commonly polycystic ovary syndrome) (",
"    <a class=\"graphic graphic_table graphicRef65205 \" href=\"UTD.htm?25/33/26139\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/2,6-8\">",
"     2,6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two conditions characterized by generalized hair growth that do",
"    <strong>",
"     not",
"    </strong>",
"    represent hirsutism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Androgen-independent hair growth, which is the soft vellus unpigmented hair that covers the entire body. In infants, this hair is called lanugo.",
"     </li>",
"     <li>",
"      Hypertrichosis, which is the term used to describe the excessive growth of androgen-independent hair that is vellus, prominent in non-sexual areas, and most commonly familial or caused by systemic disorders (hypothyroidism, anorexia nervosa, malnutrition, porphyria, and dermatomyositis) or medications (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13924?source=see_link\">",
"       diazoxide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ). Hypertrichosis is typically managed with hair removal techniques. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37014?source=see_link\">",
"       \"Removal of unwanted hair\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although women with hirsutism typically present because of concerns regarding unwanted, excessive hair growth, most also have an underlying endocrine disorder that should be identified (",
"    <a class=\"graphic graphic_table graphicRef65205 \" href=\"UTD.htm?25/33/26139\">",
"     table 1",
"    </a>",
"    ). Important clues to the severity of androgen excess and the presence of an underlying disorder can be obtained by the history, physical examination, and appropriate laboratory testing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519314618\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important goals of the evaluation are to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identify the most serious causes of hirsutism, including androgen-secreting tumors (ovarian or adrenal), and ovarian hyperthecosis. Androgen-secreting tumors are rare, particularly in premenopausal women (0.3 percent of women with hirsutism) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/11\">",
"       11",
"      </a>",
"      ], but 50 percent are malignant at the time of diagnosis. Ovarian hyperthecosis, a disorder characterized by severe hyperandrogenism and insulin resistance, is seen primarily in postmenopausal women, but occasionally occurs in premenopausal women. (See",
"      <a class=\"local\" href=\"#H291833767\">",
"       'Additional evaluation for severe hyperandrogenemia'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38662?source=see_link\">",
"       \"Ovarian hyperthecosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Identify polycystic ovary syndrome (PCOS), the underlying disorder in approximately 75 to 80 percent of women who present with hirsutism (",
"      <a class=\"graphic graphic_table graphicRef86810 \" href=\"UTD.htm?11/46/12012\">",
"       table 2",
"      </a>",
"      ). In addition to oligomenorrhea and hyperandrogenism, PCOS is associated with other important medical conditions, including obesity, insulin resistance, and an increased risk for type 2 diabetes, dyslipidemia, hypertension, and obstructive sleep apnea. The clinical features and evaluation of patients with suspected polycystic ovary syndrome are reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"       \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"       \"Diagnosis of polycystic ovary syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Identify other etiologies, including idiopathic hirsutism, congenital adrenal hyperplasia (classic and nonclassic), Cushing&rsquo;s syndrome, and hyperprolactinemia (",
"      <a class=\"graphic graphic_table graphicRef65205 \" href=\"UTD.htm?25/33/26139\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathogenesis and causes of hirsutism\", section on 'Etiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"       \"Diagnosis of polycystic ovary syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Determine the degree of emotional distress caused by the excess hair, as this has important implications for treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of hirsutism\", section on 'Indications for treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should focus initially on the time course of symptoms and the presence or absence or virilization. Features that suggest a possible androgen-secreting tumor include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recent onset, short duration (typically less than one year), or progressive worsening of hirsutism.",
"     </li>",
"     <li>",
"      Onset in the third decade of life or later, rather than near puberty.",
"     </li>",
"     <li>",
"      Signs of virilization, including frontal balding, acne, clitoromegaly, increased muscle mass, or deepening of the voice. More severe hirsutism and virilization are typically seen in ovarian hyperthecosis and androgen-secreting ovarian or adrenal tumors. Some disorders cause virilization during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38662?source=see_link\">",
"       \"Ovarian hyperthecosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=see_link\">",
"       \"Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18470?source=see_link\">",
"       \"Causes of gestational hyperandrogenism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other components of the history that help determine the underlying etiology include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menstrual history, including age at menarche, regularity of menstrual cycles, and previous oral contraceptive use. Virtually all women with severe hyperandrogenemia will have irregular menses or amenorrhea. Women with polycystic ovary syndrome (PCOS) usually have a history of irregular menses, and they often have taken oral contraceptives for irregular periods",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      for hyperandrogenic symptoms (acne and hirsutism). Prior oral contraceptive use may have masked or delayed the recognition of menstrual dysfunction or hyperandrogenic symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations of polycystic ovary syndrome in adults\", section on 'Hyperandrogenism'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Women with regular menses are unlikely to have severe hyperandrogenemia, but they may have idiopathic hyperandrogenism (normal cycles, high serum androgens) or idiopathic hirsutism (normal cycles, normal serum androgens). Depending upon the diagnostic criteria used, these women may actually fall into the category of PCOS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"       \"Diagnosis of polycystic ovary syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ethnicity &mdash; The evaluation of body hair must consider the individual&rsquo;s ethnic background. Most Asian and Native American women have little body hair, while Mediterranean women on average have substantially greater quantities of body hair even though serum androgen concentrations are similar in the three groups [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/12\">",
"       12",
"      </a>",
"      ]. Thus, an Asian woman with a few peri-areolar hairs may warrant further evaluation, whereas a Mediterranean woman with some hair growth on her upper lip might be considered normal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=see_link&amp;anchor=H5#H5\">",
"       \"Pathogenesis and causes of hirsutism\", section on 'Ethnicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Family history &mdash; A family history of hirsutism, acne, menstrual irregularity, infertility, early cardiovascular disease, and obesity suggests the possibility of PCOS in the patient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40568?source=see_link&amp;anchor=H3#H3\">",
"       \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\", section on 'Epidemiology'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A family history of irregular menses and hirsutism may also be present in women with nonclassic congenital adrenal hyperplasia (NCCAH), a disorder particularly common in Ashkenazi Jewish women [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=see_link\">",
"       \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weight history &mdash; Obese women have increased androgen production and clearance rates [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/14\">",
"       14",
"      </a>",
"      ], each of which aggravate hirsutism and increase the likelihood of menstrual irregularity, especially in those with PCOS.",
"     </li>",
"     <li>",
"      Medication history &mdash; Drugs that cause hirsutism or have other androgenic effects include anabolic steroids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      (which was often given in the past for endometriosis).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"      has been associated with the development of polycystic ovary syndrome (",
"      <a class=\"graphic graphic_table graphicRef65205 \" href=\"UTD.htm?25/33/26139\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40568?source=see_link\">",
"       \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other endocrine disorders associated with hirsutism &mdash; These usually present with the typical manifestations of the specific endocrinopathy, such as galactorrhea (hyperprolactinemia), or weight gain and hypertension (Cushing&rsquo;s syndrome) (",
"      <a class=\"graphic graphic_table graphicRef65205 \" href=\"UTD.htm?25/33/26139\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathogenesis and causes of hirsutism\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination provides information about the extent of hirsutism and sometimes about its cause. In particular, does the woman have hirsutism as opposed to hypertrichosis? Hirsutism is an increase in androgen-dependent terminal hair on the lip, chin, chest, abdomen, and back, areas where there are few or no hairs in normal women (",
"    <a class=\"graphic graphic_picture graphicRef73544 \" href=\"UTD.htm?5/5/5203\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66629 \" href=\"UTD.htm?35/12/36035\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Ferriman-Gallwey score",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simple and commonly used method to grade hair growth makes use of the modified scale of Ferriman and Gallwey, which was derived from a population study of white women in England [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/1\">",
"     1",
"    </a>",
"    ]. Using this method, nine androgen-sensitive sites are graded from 0 to 4 (",
"    <a class=\"graphic graphic_figure graphicRef66629 \" href=\"UTD.htm?35/12/36035\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/1,15\">",
"     1,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scores above 8 are considered abnormal in white and black women, a reasonable cutoff based upon data from two population studies in which only 5 percent of women had scores higher than 7 or 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. Scores between 8 and 15 are usually considered to be mild hirsutism, 16 to 25 moderate, and scores &gt;25 severe hirsutism. Of note, however, treatment decisions are often based upon the degree to which the hirsutism affects the patient&rsquo;s well-being, rather than the severity score. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hirsutism\", section on 'Indications for treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the Ferriman-Gallwey score is the most widely used method to quantify hair growth, particularly in trials of medical therapy, there are a number of limitations with its clinical use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most women have been using cosmetic measures (shaving, plucking) by the time they see a clinician.",
"     </li>",
"     <li>",
"      The expression of hair growth varies between",
"      <span class=\"nowrap\">",
"       racial/ethnic",
"      </span>",
"      groups. A lower Ferriman-Gallwey score (&gt;2) is considered to be abnormal in Asian women, as they are less likely to manifest hirsutism resulting from androgen excess [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is only a modest correlation between the quantity of hair growth and serum androgen levels [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/6,18\">",
"       6,18",
"      </a>",
"      ]. This is thought to result from the fact that stimulation of hair growth from the follicle does not depend solely on circulating androgen concentrations, but also upon local factors and variability in end-organ sensitivity to circulating androgens [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intraobserver agreement may be reasonable when using the modified Ferriman-Gallwey score [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/19\">",
"       19",
"      </a>",
"      ], but interobserver agreement appears to be poor [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The score does not account for women with focal or regional hirsutism, eg, those who have high scores in one area without a total score &gt;8.",
"     </li>",
"     <li>",
"      Women with low scores may be just as distressed by their hair growth as women with high scores. In one study of black and white women, most with a score &gt;3 consider themselves to be hirsute [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/16\">",
"       16",
"      </a>",
"      ]. Many women with low scores seek treatment because they are as distressed by their hair growth as women with high scores. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of hirsutism\", section on 'Indications for treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H471667584\">",
"    <span class=\"h3\">",
"     Other skin findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acne, seborrhea, temporal balding (which are additional signs of androgen excess), acanthosis nigricans, striae, thin skin, or bruising should be looked for on exam. The last three findings suggest the possible presence of Cushing's syndrome, whereas acanthosis nigricans suggests insulin resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Body mass index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Height, weight, and a calculation of body mass index (BMI) should be obtained. Many women with PCOS are obese (BMI &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2).",
"    </span>",
"    In addition, the pattern of body fat distribution (truncal obesity, a buffalo hump, and supraclavicular fat) may suggest the presence of Cushing's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Signs of virilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to acne, deepening of the voice, frontal (or crown) balding, increased muscle mass, and clitoromegaly indicate the presence of moderate androgen excess.",
"   </p>",
"   <p>",
"    There is significant variability in clitoral size in normal women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Clitoral enlargement is typically determined on the basis of clitoral length or the clitoral index (length times width): length &gt;10 mm or an index &gt;35 mm2 is considered above normal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779499687\">",
"    <span class=\"h3\">",
"     Abdominal and pelvic exams",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal and pelvic examination should be performed to look for mass lesions that could indicate the presence of an androgen-secreting tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Biochemical testing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519315529\">",
"    <span class=\"h3\">",
"     Serum androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the presence of hirsutism has been confirmed, the next step is measurement of serum androgens to identify those with markedly elevated levels suggestive of an androgen-secreting tumor or ovarian hyperthecosis, as both require possible surgical intervention. Serum total testosterone and DHEA-S are considered the best tests for detecting ovarian and adrenal androgen-secreting neoplasms, respectively. Moderate or markedly elevated serum androgen concentrations, eg, serum testosterone values above 150",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and serum dehydroepiandrosterone sulfate (DHEA-S) values above 700",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (18.9",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    require further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/11,24-28\">",
"     11,24-28",
"    </a>",
"    ]. The control of androgen production in women and the evaluation of severe hyperandrogenemia are discussed separately (",
"    <a class=\"graphic graphic_figure graphicRef76006 \" href=\"UTD.htm?9/16/9487\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/12?source=see_link&amp;anchor=H9#H9\">",
"     \"Steroid hormone metabolism in polycystic ovary syndrome\", section on 'Control of androgen production'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H291833767\">",
"     'Additional evaluation for severe hyperandrogenemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although it is most important to identify women with severe hyperandrogenemia, we suggest measuring serum androgens in all women presenting with hirsutism, as there is only a modest correlation between the quantity of hair growth and serum androgen levels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/18\">",
"     18",
"    </a>",
"    ], and polycystic ovary syndrome may be common even among women with mild hirsutism (Ferriman-Gallwey scores between 8 and 15) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach is consistent with the Androgen Excess Society guidelines that suggest measuring serum androgens in all women with hirsutism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/11\">",
"     11",
"    </a>",
"    ]. The Endocrine Society guidelines suggest against routine measurement of serum testosterone in women with mild hirsutism only [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/29\">",
"     29",
"    </a>",
"    ], but do suggest testing in women with moderate to severe hirsutism, or for hirsutism associated with irregular menses, obesity, signs of virilization, or rapid progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H600539558\">",
"    <span class=\"h4\">",
"     Testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest measurement of serum total testosterone concentration, because it provides the best overall estimate of androgen production in hirsute women. Although serum free testosterone may be the more sensitive test for the presence of hyperandrogenic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/30\">",
"     30",
"    </a>",
"    ], currently available direct assays are inaccurate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/31\">",
"     31",
"    </a>",
"    ]. Free testosterone by equilibrium dialysis or calculated using total testosterone and SHBG results are the preferred methods, but are not routinely indicated, because serum total testosterone measurements readily identify those women who need further evaluation for a possible androgen-secreting tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total testosterone values above 150",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    should prompt additional evaluation for a testosterone-secreting ovarian or adrenal tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/25,26,32,33\">",
"     25,26,32,33",
"    </a>",
"    ], and ovarian hyperthecosis, a disorder characterized by severe hyperandrogenism and insulin resistance. Both disorders are seen more commonly in postmenopausal women, but occur occasionally in premenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=see_link&amp;anchor=H11#H11\">",
"     \"Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=see_link&amp;anchor=H1#H1\">",
"     \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38662?source=see_link&amp;anchor=H952680715#H952680715\">",
"     \"Ovarian hyperthecosis\", section on 'Biochemical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most women with PCOS have serum testosterone concentrations below 150",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    often in the normal range (20 to 60",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [0.69-2.1",
"    <span class=\"nowrap\">",
"     nmol/L]",
"    </span>",
"    for many assays). Although the degree of hyperandrogenemia may not correlate well with the severity of hirsutism, it does appear to correlate with metabolic risks observed in women with PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When measuring serum androgens in women who have been taking an oral contraceptive, it is best to discontinue the medications for at least 8 to 12 weeks, as it takes at least this length of time for measured androgens and SHBG to return to basal values [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H253047635\">",
"    <span class=\"h4\">",
"     DHEA-S",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum DHEA-S, an adrenal androgen, should also be measured; concentrations &gt;700",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (18.9",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    raise suspicion for an adrenal tumor, most importantly adrenal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/11,24,27,28\">",
"     11,24,27,28",
"    </a>",
"    ]. Adults with hormone-secreting adrenocortical carcinomas usually present with Cushing's syndrome alone (45 percent), or a mixed Cushing's and virilization syndrome, with overproduction of both glucocorticoids and androgens (25 percent). Fewer than 10 percent present with virilization alone, but the presence of virilization in a patient with an adrenal neoplasm suggests an adrenal carcinoma rather than an adenoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519315726\">",
"    <span class=\"h3\">",
"     17-hydroxyprogesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;We also suggest testing for nonclassic 21-hydroxylase deficiency in women who are Ashkenazi Jewish, because the prevalence of the disorder is higher in these women than in other ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/13\">",
"     13",
"    </a>",
"    ]. A morning value of 17-hydroxyprogesterone greater than 200",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    in the early follicular phase strongly suggests the diagnosis, which may be confirmed by a high dose (250 mcg) ACTH (1-24) (cosyntropin) stimulation test. The response to cosyntropin is exaggerated, most patients having values exceeding 1500",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (43",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=see_link\">",
"     \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/21/1367?source=see_link\">",
"     \"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11353863\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hirsutism and irregular menses should have a pregnancy test and measurement of serum prolactin. These women should also have the same tests as women who have",
"    <span class=\"nowrap\">",
"     oligomenorrhea/amenorrhea",
"    </span>",
"    but no hirsutism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some hirsute women have symptoms and signs of cortisol excess (such as centripetal obesity, hypertension, purple striae) that suggest Cushing's syndrome. These women should have a 24-hour urinary excretion of cortisol and creatinine measured. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional evaluation of women with suspected polycystic ovary syndrome, including assessment of ovulatory status, lipid profile, and screening for type 2 diabetes are reviewed separately. In some populations with PCOS (eg, Icelandic women), measurement of serum androstenedione may be important for documenting hyperandrogenism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291833767\">",
"    <span class=\"h2\">",
"     Additional evaluation for severe hyperandrogenemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation is indicated in all women when an ovarian androgen-secreting tumor is suspected (serum total testosterone &gt;150",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [5.2",
"    <span class=\"nowrap\">",
"     nmol/L]).",
"    </span>",
"    We suggest pelvic ultrasound as the next diagnostic step. For women with evidence of an adrenal source of androgen excess (DHEA-S &gt;700",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [18.9",
"    <span class=\"nowrap\">",
"     &micro;mol/L]),",
"    </span>",
"    we suggest adrenal CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291833774\">",
"    <span class=\"h3\">",
"     Pelvic ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-resolution pelvic ultrasonography with a transvaginal probe can identify ovarian follicles and cysts as small as 3 to 5 mm in diameter. It is therefore a safe and effective way to look for polycystic ovary morphology and to screen for ovarian androgen-secreting tumors. Suspicious findings include large cysts, solid masses, and complex cysts that do not resolve spontaneously in two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the sensitivity and specificity of ultrasonography for the diagnosis of ovarian tumors in hyperandrogenic women has not been determined. Small hilus-cell tumors of the ovary that produce large amounts of testosterone may not be seen by ultrasonography or even at the time of surgery. In addition, other tumors, including androgen-secreting sex cord stromal tumors, are often not visualized [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/37\">",
"     37",
"    </a>",
"    ]. The ovaries may be described as &ldquo;normal&rdquo; size, or slight asymmetry may be detected. Pelvic MRI and (18)F-fluorodeoxyglucose PET imaging have identified small tumors in case reports, but data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=see_link&amp;anchor=H727742#H727742\">",
"     \"Overview of sex cord-stromal tumors of the ovary\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasonography in women with ovarian hyperthecosis usually shows a bilateral increase in ovarian stroma. Unlike PCOS, where the ovaries characteristically have a multifollicular appearance with 12 or more antral follicles of 2 to 9 mm per ovary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ovarian volume &gt;10 cm",
"    <sup>",
"     3",
"    </sup>",
"    , few cysts are seen in severe hyperthecosis and the ovaries appear more solid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38662?source=see_link&amp;anchor=H952680501#H952680501\">",
"     \"Ovarian hyperthecosis\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, pelvic ultrasonography is indicated in patients with an elevated serum testosterone concentration when an ovarian androgen-secreting tumor is suspected (total testosterone &gt;150",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [5.2",
"    <span class=\"nowrap\">",
"     nmol/L]).",
"    </span>",
"    However, failure to identify a tumor does not rule out its presence, as these tumors may be very small.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291833781\">",
"    <span class=\"h3\">",
"     Adrenal imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal imaging is indicated to look for an adrenal mass if the woman has a markedly elevated serum DHEA-S concentration (DHEA-S &gt;700",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [18.9",
"    <span class=\"nowrap\">",
"     &micro;mol/L]).",
"    </span>",
"    Adrenal CT is the imaging test of choice, and should readily identify androgen-secreting adrenal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Radiologic testing is otherwise not indicated, and may be misleading, because nonfunctioning adrenal masses (adrenal incidentalomas) are common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adrenal disorders that may be diagnosed during the evaluation for hirsutism and require surgery include adrenal adenomas, ACTH-independent Cushing&rsquo;s syndrome, and adrenal carcinoma (uncommon in premenopausal women). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291833788\">",
"    <span class=\"h3\">",
"     Ovarian and adrenal vein sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined ovarian and adrenal vein sampling (selective venous sampling) is sometimes performed for further evaluation in women with high serum testosterone concentrations (T &gt;150",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [5.2",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    and normal pelvic ultrasonography and adrenal imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/41\">",
"     41",
"    </a>",
"    ]. In this setting, the ovary is likely to be the source of androgen hypersecretion, because adrenal tumors are almost always visualized on adrenal CT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], while ovarian tumors are often too small to be seen on imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H291833781\">",
"     'Adrenal imaging'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H291833774\">",
"     'Pelvic ultrasonography'",
"    </a>",
"    above.) This scenario is far more common in postmenopausal women than premenopausal women.",
"   </p>",
"   <p>",
"    The procedure includes selective catheterization of the ovarian and adrenal veins to demonstrate a left-to-right difference in androgen concentrations. However, this procedure is technically difficult; in one report, catheterization of all four veins (two ovarian, two adrenal) was successful in only 10 of 38 patients (27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/42\">",
"     42",
"    </a>",
"    ]. In addition, there is no consensus on the testosterone gradient that localizes the androgen source [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. It should only be performed by an experienced radiologist.",
"    <br/>",
"    <br/>",
"    In premenopausal women, we typically only suggest this procedure in those interested in future fertility. In this instance, successful localization to one ovary would change management (eg, the patient could undergo a unilateral rather than a bilateral oophorectomy if a tumor source was located). In some cases, the procedure is performed intraoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in premenopausal women who are not interested in future fertility and in postmenopausal women, we suggest bilateral oophorectomy rather than further diagnostic evaluation with ovarian vein sampling. In these women, the potential risks of the procedure are unlikely to outweigh the benefits of a definitive surgical procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An exception would be the patient presenting with gradual onset hirsutism and virilization (over years) with a small adrenal nodule (incidentaloma). The gradual onset in this scenario is more suggestive of a benign ovarian source of androgens than adrenal carcinoma. Therefore, a sampling procedure would be indicated before proceeding with adrenal exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9721/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/56/9090?source=see_link\">",
"       \"Patient information: Hirsutism (excess hair growth in women) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=see_link\">",
"       \"Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hirsutism is a clinical diagnosis, defined by the presence of excess terminal hair growth (dark, coarse hairs) in androgen-sensitive areas (eg, upper lip, chin, midsternum, upper abdomen, back, and buttocks). (See",
"      <a class=\"local\" href=\"#H253046823\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A simple and commonly used method to grade hair growth makes use of the modified scale of Ferriman and Gallwey, which grades nine androgen-sensitive sites on a scale from 0 to 4 (",
"      <a class=\"graphic graphic_figure graphicRef66629 \" href=\"UTD.htm?35/12/36035\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Although women with hirsutism typically present because of cosmetic concerns, most also have an underlying endocrine disorder (most commonly polycystic ovary syndrome) that should be identified. (See",
"      <a class=\"local\" href=\"#H519314618\">",
"       'Goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important goal of the evaluation is to identify the most serious causes of hirsutism, including androgen-secreting tumors (ovarian or adrenal). Features that suggest a possible androgen-secreting tumor include (see",
"      <a class=\"local\" href=\"#H519314618\">",
"       'Goals'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Recent onset, short duration (typically less than one year), progressive worsening of hirsutism",
"     </li>",
"     <li>",
"      Onset in the third decade of life or later, rather than near puberty",
"     </li>",
"     <li>",
"      Signs of virilization, including frontal balding, acne, clitoromegaly, increased muscle mass, or deepening of the voice",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest measuring serum total testosterone and DHEA-S in all women presenting with hirsutism. Other testing depends upon the clinical scenario. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Biochemical testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest an adrenal CT scan to look for an adrenal androgen-secreting tumor if the serum DHEA-S concentration is &ge;700",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (18.9",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H291833781\">",
"       'Adrenal imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a transvaginal ultrasound if the serum total testosterone concentration is &ge;150",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (5.2",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H291833774\">",
"       'Pelvic ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combined ovarian and adrenal vein sampling (selective venous sampling) is sometimes performed for further evaluation in women with high serum testosterone concentrations (T &gt;150",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      [5.2",
"      <span class=\"nowrap\">",
"       nmol/L])",
"      </span>",
"      and normal pelvic ultrasonography and adrenal imaging. In this setting, the ovary is likely to be the source of androgen hypersecretion, because adrenal tumors are almost always visualized on adrenal CT, while ovarian tumors are often too small to be seen on imaging studies. (See",
"      <a class=\"local\" href=\"#H291833788\">",
"       'Ovarian and adrenal vein sampling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest the routine use of selective venous sampling to localize the side of androgen hypersecretion in women with severe hyperandrogenemia and negative ovarian and adrenal imaging (with the exceptions noted above). (See",
"      <a class=\"local\" href=\"#H291833788\">",
"       'Ovarian and adrenal vein sampling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/1\">",
"      FERRIMAN D, GALLWEY JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/2\">",
"      Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005; 353:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/3\">",
"      Lipton MG, Sherr L, Elford J, et al. Women living with facial hair: the psychological and behavioral burden. J Psychosom Res 2006; 61:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/4\">",
"      Hahn S, Janssen OE, Tan S, et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 2005; 153:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/5\">",
"      Clayton WJ, Lipton M, Elford J, et al. A randomized controlled trial of laser treatment among hirsute women with polycystic ovary syndrome. Br J Dermatol 2005; 152:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/6\">",
"      Souter I, Sanchez LA, Perez M, et al. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol 2004; 191:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/7\">",
"      Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000; 21:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/8\">",
"      Di Fede G, Mansueto P, Pepe I, et al. High prevalence of polycystic ovary syndrome in women with mild hirsutism and no other significant clinical symptoms. Fertil Steril 2010; 94:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/9\">",
"      McKenna TJ. Screening for sinister causes of hirsutism. N Engl J Med 1994; 331:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/10\">",
"      Rittmaster RS. Clinical review 73: Medical treatment of androgen-dependent hirsutism. J Clin Endocrinol Metab 1995; 80:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/11\">",
"      Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2012; 18:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/12\">",
"      Carmina E, Koyama T, Chang L, et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992; 167:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/13\">",
"      Speiser PW. Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Endocrinol Metab Clin North Am 2001; 30:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/14\">",
"      Kirschner MA, Samojlik E, Silber D. A comparison of androgen production and clearance in hirsute and obese women. J Steroid Biochem 1983; 19:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/15\">",
"      Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/16\">",
"      DeUgarte CM, Woods KS, Bartolucci AA, Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab 2006; 91:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/17\">",
"      Cheewadhanaraks S, Peeyananjarassri K, Choksuchat C. Clinical diagnosis of hirsutism in Thai women. J Med Assoc Thai 2004; 87:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/18\">",
"      Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000; 21:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/19\">",
"      Barth JH. How robust is the methodology for trials of therapy in hirsute women? Clin Endocrinol (Oxf) 1996; 45:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/20\">",
"      Wild RA, Vesely S, Beebe L, et al. Ferriman Gallwey self-scoring I: performance assessment in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:4112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/21\">",
"      Lloyd J, Crouch NS, Minto CL, et al. Female genital appearance: \"normality\" unfolds. BJOG 2005; 112:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/22\">",
"      Verkauf BS, Von Thron J, O'Brien WF. Clitoral size in normal women. Obstet Gynecol 1992; 80:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/23\">",
"      Tagatz GE, Kopher RA, Nagel TC, Okagaki T. The clitoral index: a bioassay of androgenic stimulation. Obstet Gynecol 1979; 54:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/24\">",
"      Zumoff B, Rosenfeld RS, Strain GW, et al. Sex differences in the twenty-four-hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults. J Clin Endocrinol Metab 1980; 51:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/25\">",
"      Meldrum DR, Abraham GE. Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors. Obstet Gynecol 1979; 53:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/26\">",
"      Friedman CI, Schmidt GE, Kim MH, Powell J. Serum testosterone concentrations in the evaluation of androgen-producing tumors. Am J Obstet Gynecol 1985; 153:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/27\">",
"      Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/28\">",
"      d'Alva CB, Abiven-Lepage G, Viallon V, et al. Sex steroids in androgen-secreting adrenocortical tumors: clinical and hormonal features in comparison with non-tumoral causes of androgen excess. Eur J Endocrinol 2008; 159:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/29\">",
"      Rousset P, Gompel A, Christin-Maitre S, et al. Ovarian hyperthecosis on grayscale and color Doppler ultrasound. Ultrasound Obstet Gynecol 2008; 32:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/30\">",
"      Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/31\">",
"      Miller KK, Rosner W, Lee H, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab 2004; 89:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/32\">",
"      O'Driscoll JB, Mamtora H, Higginson J, et al. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol (Oxf) 1994; 41:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/33\">",
"      Derksen J, Nagesser SK, Meinders AE, et al. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 1994; 331:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/34\">",
"      Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/35\">",
"      S&aacute;nchez LA, P&eacute;rez M, Centeno I, et al. Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study. Fertil Steril 2007; 87:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/36\">",
"      Welt CK, Arason G, Gudmundsson JA, et al. Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations. J Clin Endocrinol Metab 2006; 91:4361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/37\">",
"      Demidov VN, Lipatenkova J, Vikhareva O, et al. Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors. Ultrasound Obstet Gynecol 2008; 31:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/38\">",
"      Faria AM, Perez RV, Marcondes JA, et al. A premenopausal woman with virilization secondary to an ovarian Leydig cell tumor. Nat Rev Endocrinol 2011; 7:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/39\">",
"      Cavlan D, Bharwani N, Grossman A. Androgen- and estrogen-secreting adrenal cancers. Semin Oncol 2010; 37:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/40\">",
"      Cordera F, Grant C, van Heerden J, et al. Androgen-secreting adrenal tumors. Surgery 2003; 134:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/41\">",
"      Dickerson RD, Putman MJ, Black ME, et al. Selective ovarian vein sampling to localize a Leydig cell tumor. Fertil Steril 2005; 84:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/42\">",
"      Kaltsas GA, Mukherjee JJ, Kola B, et al. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women? Clin Endocrinol (Oxf) 2003; 59:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/43\">",
"      Petersons CJ, Burt MG. The utility of adrenal and ovarian venous sampling in the investigation of androgen-secreting tumours. Intern Med J 2011; 41:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/44\">",
"      Bohlmann MK, Rabe T, Sinn HP, et al. Intraoperative venous blood sampling to localize a small androgen-producing ovarian tumor. Gynecol Endocrinol 2005; 21:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9721/abstract/45\">",
"      Alpa&ntilde;&eacute;s M, Gonz&aacute;lez-Casbas JM, S&aacute;nchez J, et al. Management of postmenopausal virilization. J Clin Endocrinol Metab 2012; 97:2584.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7441 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9721=[""].join("\n");
var outline_f9_31_9721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H325960\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H253046823\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H519314618\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Ferriman-Gallwey score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H471667584\">",
"      - Other skin findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Body mass index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Signs of virilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H779499687\">",
"      - Abdominal and pelvic exams",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Biochemical testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H519315529\">",
"      - Serum androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H600539558\">",
"      Testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H253047635\">",
"      DHEA-S",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H519315726\">",
"      - 17-hydroxyprogesterone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11353863\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H291833767\">",
"      Additional evaluation for severe hyperandrogenemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H291833774\">",
"      - Pelvic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H291833781\">",
"      - Adrenal imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H291833788\">",
"      - Ovarian and adrenal vein sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7441\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7441|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/12/36035\" title=\"figure 1\">",
"      Grading of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/16/9487\" title=\"figure 2\">",
"      Theca cell androgen production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7441|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/5/5203\" title=\"picture 1\">",
"      Hirsutism in PCOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7441|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/33/26139\" title=\"table 1\">",
"      Causes of hirsutism in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/46/12012\" title=\"table 2\">",
"      Diagnostic criteria PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18470?source=related_link\">",
"      Causes of gestational hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/21/1367?source=related_link\">",
"      Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40568?source=related_link\">",
"      Epidemiology and pathogenesis of the polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=related_link\">",
"      Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38662?source=related_link\">",
"      Ovarian hyperthecosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=related_link\">",
"      Overview of sex cord-stromal tumors of the ovary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=related_link\">",
"      Pathogenesis and causes of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/24/13698?source=related_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/56/9090?source=related_link\">",
"      Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37014?source=related_link\">",
"      Removal of unwanted hair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=related_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/12?source=related_link\">",
"      Steroid hormone metabolism in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35416?source=related_link\">",
"      Treatment of hirsutism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_31_9722="Clinical presentation, pathologic features, and diagnosis of Szary syndrome";
var content_f9_31_9722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9722/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9722/contributors\">",
"     Elise A Olsen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9722/contributors\">",
"     Alain H Rook, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9722/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9722/contributors\">",
"     Timothy M Kuzel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9722/contributors\">",
"     John A Zic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/31/9722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/31/9722/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/31/9722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H449460985\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;S&eacute;zary syndrome (SS) and mycosis fungoides (MF) are the most common subtypes of cutaneous T cell lymphoma (CTCL) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MF is a mature T cell non-Hodgkin lymphoma with presentation in the skin but with potential involvement of the nodes, blood, and viscera [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/2\">",
"       2",
"      </a>",
"      ]. Skin lesions include patches or plaques that may be localized or widespread, tumors, and erythroderma.",
"     </li>",
"     <li>",
"      S&eacute;zary syndrome is defined as a distinctive erythrodermic CTCL with a leukemic involvement of malignant T cells clonally matching that in the skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SS may be considered to have either evolved from MF (ie, not initially meeting the criteria for SS), or may present",
"    <em>",
"     de novo",
"    </em>",
"    with full blown signs and symptoms of the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/1\">",
"     1",
"    </a>",
"    ]. In either case, both MF and SS are defined histologically and staged by the same criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast to",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    MF, SS is much more symptomatic, has a lower potential for remission, and lower expected survival.",
"   </p>",
"   <p>",
"    In 2007, the staging system for MF and SS was revised to incorporate blood involvement and a standardized definition of erythroderma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, the treatment of SS has advanced considerably this century [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/3\">",
"     3",
"    </a>",
"    ]. These changes in the staging and treatment of SS offer the potential for future revision of the survival curves published on SS prior to these advances.",
"   </p>",
"   <p>",
"    This topic review will discuss the clinical presentation, pathologic features, diagnosis, and differential diagnosis of S&eacute;zary syndrome. The diagnosis of mycosis fungoides and the management of these two entities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449461398\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a small percentage of cases of SS are associated with human T-lymphotropic viruses type 1 and 2",
"    <span class=\"nowrap\">",
"     (HTLV1/2),",
"    </span>",
"    which are endemic in southern Japan, the Caribbean islands, and part of the Middle East, the cause of most cases of SS remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/3\">",
"     3",
"    </a>",
"    ]. The tumor cells appear to be derived from skin homing CD4 positive T cells or central memory T cells that typically express cutaneous lymphocyte antigen (CLA) and high levels of the chemokine receptors CCR4 and CCR7 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], which provides them with the capacity to traffic bi-directionally into and out of the skin in response to the appropriate chemokines. They are recognized by the frequent loss of CD26 in perhaps more than 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/6\">",
"     6",
"    </a>",
"    ], as well as the loss of CD7 in about 50 percent of cases. The typical immunophenotype of the abnormal peripheral blood T cell population is CD3+, CD4+, CD7-, CD26-, CD8-. Occasionally, SS can occur with the malignant population demonstrating a CD8+ phenotype. SS with the CD8+ phenotype can be associated with retroviral infections",
"    <span class=\"nowrap\">",
"     (HTLV-1/2",
"    </span>",
"    or HIV). As such, it is recommended that these serologies be obtained in this setting. (See",
"    <a class=\"local\" href=\"#H1060895\">",
"     'Immunophenotyping confirming T cell origin (CD3+, CD4+)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are substantial data that patients with SS exhibit endogenous immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The cause of impaired immune function has been attributed, at least partially, to the increased production of type 2 T cell (Th2) cytokines by the malignant clone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/7\">",
"     7",
"    </a>",
"    ], which can antagonize Th1 immunity leading to decreased IL-12 and interferon gamma production, which are critical for anti-tumor immunity. Activated T cells of patients with SS may also produce increased IL-10 and TGF-beta, which can further complicate the impairment of cell-mediated immunity. In some cases, the malignant T cells can behave like regulatory T cells by manifesting Foxp3 and increased CTLA4 expression with enhanced production of IL-10 or TGF-beta, leading to suppression of normal T cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Increased production of Th2 cytokines have been implicated in some of the characteristic immune abnormalities identified among patients with SS, which include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased T cell responses to antigens and mitogens",
"     </li>",
"     <li>",
"      Impaired cell-mediated cytotoxicity, including natural killer cell activity",
"     </li>",
"     <li>",
"      Increased levels of serum IgE",
"     </li>",
"     <li>",
"      Peripheral eosinophilia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other causes for depressed Th1 immunity and impaired cell-mediated immunity include increased expression of programmed death domain 1 (PD-1) on the malignant T cells, which can result in the inhibition of cytotoxic T cell function. In addition, the malignant T cells fail to normally upregulate CD40 ligand expression during activation, which may lead to impaired activation and differentiation of dendritic cells (DCs). It is quite clear that a decline in the number and function of DCs parallels an increase in the circulating burden of malignant T cells. A substantial loss of the normal T cell repertoire also appears to parallel the progression of disease and likely contributes to immune dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/11\">",
"     11",
"    </a>",
"    ]. These findings have helped guide immune modulatory therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple defects of proapoptotic pathways have been identified, including decreased expression of Fas (CD95), which may be due to hypermethylation of the Fas gene promoter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This abnormality may be overcome by treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    as well as the use of interferon alpha or gamma, leading to the upregulation of CD95 expression, rendering cells more susceptible to Fas ligand mediated death. Other defects include increased expression of the apoptosis inhibitor cFLIP, as well as tumor cell loss of TRAIL-receptor 2 leading to resistance to TRAIL. Defects in apoptosis are presumed to lead to accumulation of the malignant T cells",
"    <em>",
"     in vivo",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    Molecular gene expression profiles have been identified that lend an understanding to the preproliferative nature of the malignant T cells, as well as to the immune dysregulation. As an example, alterations in expression of certain transcription factors important for T cell differentiation, particularly upregulation of GATA-3, and downregulation of expression of Stat 4, may account for the Th2 phenotype in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. The observation of the loss of nuclear pro-IL16 provides further insight into mechanisms underlying the enhanced proliferation of the malignant T cell population. The presence of nuclear pro-IL16 normally contributes to T cell quiescence. Therefore, its loss would lead to cell cycle progression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/16\">",
"     16",
"    </a>",
"    ]. Other valuable insights include the observation that T-plastin is expressed in the malignant T cells of patients with SS. This gene is not normally expressed in hematopoietic cells, and therefore its aberrant expression can facilitate the identification of the lymphoma cells for diagnostic and therapeutic purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Growing evidence from gene expression profiles, microRNA profiling, and cell marker studies suggests that mycosis fungoides and S&eacute;zary syndrome may be separate entities with differing pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/5,18-20\">",
"     5,18-20",
"    </a>",
"    ]. Comparative genomic hybridization has identified chromosomal abnormalities that occur in both mycosis fungoides and S&eacute;zary syndrome and abnormalities that are present in either mycosis fungoides or S&eacute;zary syndrome, but not both [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Importantly, the malignant T cells of patients with SS have been shown to express CD27, CCR7, L-selectin, and CCR4, which are markers of central memory T cells. In contrast, the malignant T cells of patients with mycosis fungoides fail to express CCR7, L-selectin, and CD27 but do express high levels of CCR4 and CLA, which is typical of skin-resident effector T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/5\">",
"     5",
"    </a>",
"    ]. Hypotheses regarding the pathogenesis of mycosis fungoides are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449461419\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence of SS is unknown. In the United States, analysis of the population based Surveillance, Epidemiology and End Results (SEER) data from 2001 to 2005 has estimated the incidence at 0.8 cases per million persons per year with a male:female ratio of 2.11 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/25\">",
"     25",
"    </a>",
"    ]. Similarly, data from the Cancer Registry of Norway from 2000 to 2003 estimated the incidence at approximately 0.9 cases per million persons per year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. SS is a disease of older adults with very few cases reported among patients younger than 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/26\">",
"     26",
"    </a>",
"    ]. In the United States, the incidence appears higher among whites (0.36 cases per million persons per year) than among blacks (0.04 cases per million persons per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449461426\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SS commonly present with erythroderma and generalized lymphadenopathy developing over weeks to months. The skin is often pruritic and the patient's quality of life can be profoundly affected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/28\">",
"     28",
"    </a>",
"    ]. Other clinical manifestations include opportunistic infections, alopecia, and, less commonly, involvement of other organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059750\">",
"    <span class=\"h2\">",
"     Signs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449462700\">",
"    <span class=\"h3\">",
"     Skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SS commonly present with widespread erythema (",
"    <a class=\"graphic graphic_picture graphicRef72342 \" href=\"UTD.htm?11/30/11745\">",
"     picture 1",
"    </a>",
"    ) that can be finely scaly, indurated, or even resemble livido reticularis. The severity of erythema and the body surface area (BSA) involved may wax and wane, but at some point in the disease course the skin involvement should meet the standard definition of coverage of 80 percent BSA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Skin lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike in mycosis fungoides, patients with SS do not usually evolve through patches and plaques, but tend to present with diffuse skin involvement. Other skin lesions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keratosis pilaris-like lesions &mdash; Inflamed follicular based papules or scale may signal follicular involvement (",
"      <a class=\"graphic graphic_picture graphicRef83372 \" href=\"UTD.htm?11/54/12128\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Alopecia &mdash; Alopecia is common and can present as reduced hair density diffusely over the scalp and body or as patches of alopecia (",
"      <a class=\"graphic graphic_picture graphicRef83374 graphicRef83373 \" href=\"UTD.htm?40/41/41623\">",
"       picture 3A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ectropion &mdash; An outward turning of the lower eyelid with increased exposure of the ocular surface and sensitive mucous membranes of the inner lid can develop because of the tautness and induration in the skin and may be associated with disruption of normal tear drainage patterns.",
"     </li>",
"     <li>",
"      Keratoderma &mdash; A thickened retention of keratin on the palms and soles, so called keratoderma is a common finding and one that can also help to differentiate SS from other causes of erythroderma (",
"      <a class=\"graphic graphic_picture graphicRef83371 \" href=\"UTD.htm?11/32/11783\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hypertrophic nails &mdash; Nails may become hypertrophic secondary to posterior nail fold involvement.",
"     </li>",
"     <li>",
"      Erosions and superinfection &mdash; Patients are often colonized with Staphylococcus aureus, and erosions and superinfection from constant scratching are common.",
"     </li>",
"     <li>",
"      Lichenification &mdash; Diffuse lichenification, characterized as thickened skin with increased skin lines, may occur with long-standing disease, and fissures are common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059786\">",
"    <span class=\"h3\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral lymphadenopathy is common and on biopsy usually demonstrates either dermatopathic changes or those diagnostic of lymphoma, both related to the underlying cutaneous lymphoma. (See",
"    <a class=\"local\" href=\"#H1060019\">",
"     'Lymph node biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059795\">",
"    <span class=\"h3\">",
"     Viscera",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence of visceral involvement in patients with S&eacute;zary syndrome (SS) as currently defined is unknown. Initial studies reported that a significant minority of patients will present with splenic enlargement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone marrow involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Bone marrow involvement is not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], but as bone marrow biopsy is not part of the current recommended staging evaluation, the exact incidence is unknown. Other visceral involvement, especially of the liver, lung, and gastrointestinal tract is uncommon at the time of diagnosis, but may occur late in the course of the disease, usually after failure of various treatments.",
"   </p>",
"   <p>",
"    An assessment of potential visceral involvement is included in the initial staging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/2\">",
"     2",
"    </a>",
"    ]. A computed tomography (CT), or a combined positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET)/CT,",
"    </span>",
"    in patients with biopsy proven erythrodermic MF or erythroderma and lymphadenopathy is recommended. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4713?source=see_link&amp;anchor=H1118879#H1118879\">",
"     \"Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059823\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059831\">",
"    <span class=\"h3\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus is the most common and the most debilitating symptom of patients with SS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/31\">",
"     31",
"    </a>",
"    ]. It is not necessarily related to the degree of blood involvement or the extent and depth of erythema. High doses of antihistamines are generally ineffective in controlling the pruritus. Other than therapy that delivers remission of the cancer, systemic steroids are often the only treatment that offers some relief. Other negative effects associated with pruritus include sleep dysfunction, anxiety, and depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H33#H33\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Pruritus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059838\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63648088\">",
"    <span class=\"h3\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with S&eacute;zary syndrome (SS) are at increased risk for infection due to a combination of immune dysfunction and physical factors. Patients with SS demonstrate impaired cellular and humoral immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/3\">",
"     3",
"    </a>",
"    ]. They have an increase in the severity of viral (eg, herpes) and bacterial infections. In one study, the majority of patients with SS demonstrated colonization with Staphylococcus aureus in the skin or nares [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/32\">",
"     32",
"    </a>",
"    ]. Colonized patients treated with antibiotics to eradicate the bacteria often demonstrate clinical improvement of signs of skin involvement with the lymphoma. There have also been reports of progressive multifocal leukoencephalopathy due to polyomavirus in patients with SS in the absence of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H449461398\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449462735\">",
"    <span class=\"h3\">",
"     Second malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the SEER (Surveillance, Epidemiology, and End Results Program) United States population-based and university referral center registries have demonstrated an increased incidence of second cancers, especially lymphoma, in patients with mycosis fungoides or S&eacute;zary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. As an example, an analysis of the SEER registry reported 197 second malignancies among 1798 patients with an initial diagnosis of mycosis fungoides or S&eacute;zary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/34\">",
"     34",
"    </a>",
"    ]. When compared with age-, sex-, and race-matched persons from the general population, patients with mycosis fungoides or S&eacute;zary syndrome had a significantly higher rate of the following (as expressed using the standardized incidence ratio [SIR]):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hodgkin lymphoma (SIR 17.14; 95% confidence interval [CI] 6.25-37.26)",
"     </li>",
"     <li>",
"      Non-Hodgkin lymphoma (SIR 5.08; 95% CI 3.34-7.38)",
"     </li>",
"     <li>",
"      Melanoma (SIR 2.60; 95% CI 1.25-4.79)",
"     </li>",
"     <li>",
"      Urinary cancer (SIR 1.74; 95% CI 1.08-2.66)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449462742\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059997\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060012\">",
"    <span class=\"h3\">",
"     Light microscopic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;A biopsy of representative erythrodermic skin with routine hematoxylin and eosin staining technique is rarely diagnostic of mycosis fungoides (MF). Generally there are atypical lymphocytes in a sparse dermal infiltrate along with epidermotropism (movement of the atypical lymphocytes into the epidermis), which is suggestive, but not diagnostic, of MF. The more diagnostic intra-epidermal aggregates of atypical cells (ie, Pautrier&rsquo;s microabscesses) may or may not be present. Significant edema and a nonspecific infiltrate of inflammatory T cells may predominate, making diagnosis more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/37\">",
"     37",
"    </a>",
"    ]. The histological findings in the affected skin in SS and MF are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Skin biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060880\">",
"    <span class=\"h3\">",
"     Clonality of the T cell receptor (TCR) gene rearrangement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clonality of the T cell receptor (TCR) gene rearrangement by polymerase chain reaction (PCR) or Southern blot is supportive of the diagnosis of mycosis fungoides (MF) and SS, particularly if the clonality in the skin matches that in the blood. However, the presence of a clone in the skin is not diagnostic of SS or MF and can be seen in many benign skin disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCR is the more sensitive of the test procedures but is dependent on finding enough tumor cells in a specimen; thus, the size and selection of the skin biopsy is key. Clonality studies can be done confidently on formalin fixed tissue using the BioMed2 primers so that taking a separate biopsy solely for fresh tissue technique is not necessary. The initial clonality testing typically first addresses potential",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    rearrangements since this is the final part of a chain reaction in lymphocyte maturation. However, TCR",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    clonality testing can be negative in cases demonstrating",
"    <span class=\"nowrap\">",
"     alfa/beta",
"    </span>",
"    clonal rearrangement. It is therefore recommended that cases without clonality by",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    testing have",
"    <span class=\"nowrap\">",
"     alfa/beta",
"    </span>",
"    testing performed. Screening for",
"    <span class=\"nowrap\">",
"     alfa/beta",
"    </span>",
"    rearrangement may be performed quickly by immunohistochemistry using the BF-1 antibody. Expression of BF-1 signifies expression of the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060895\">",
"    <span class=\"h3\">",
"     Immunophenotyping confirming T cell origin (CD3+, CD4+)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunophenotype of the tumor cells is usually established by immunohistochemistry using formalin fixed tissue. Immunophenotyping that confirms T cell origin (CD3+, CD4+) and shows deletion of mature T cell antigens (&lt;10 percent CD7+ T cells, &lt;50 percent CD2+,CD3+",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CD5+ T cells) is supportive of the diagnosis of mycosis fungoides (MF) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/40\">",
"     40",
"    </a>",
"    ] as well as S&eacute;zary syndrome (SS), although at this time using these criteria as part of an algorithm only officially applies to early MF and not SS. Variants of SS that express CD8 are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Epidermal/dermal",
"    </span>",
"    discordance, when the antigens (CD2, CD3, CD5 or CD7) are deficient among the cells restricted to the epidermis but are present in the cells in the dermis, is also supportive of a diagnosis of MF in patch stage disease and, by extrapolation, in the erythroderma of SS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Immunophenotyping'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060019\">",
"    <span class=\"h2\">",
"     Lymph node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SS often have peripheral lymphadenopathy, defined by the",
"    <span class=\"nowrap\">",
"     ISCL/EORTC",
"    </span>",
"    guidelines as nodes at least 1.5 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast to other types of primary cutaneous lymphoma, enlarged lymph nodes in MF and SS may histopathologically demonstrate reactive change, dermatopathic features, or frank lymphoma. It is important to perform an excisional biopsy and not a core biopsy or fine needle aspirate to make this distinction, as lymph node staging in MF and SS is dependent on architectural changes. The amount",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    size of the abnormal lymphocytes and the degree of effacement of the normal lymph node architecture are used to give a grade of dermatopathic involvement with one of two different scoring systems (NCI and Dutch) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/2\">",
"     2",
"    </a>",
"    ]. A NCI grade LN4 and a Dutch grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    both are indicative of nodal lymphoma. TCR gene rearrangement clonality is usually present with nodal lymphoma and would generally be expected to match that found in the skin and blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63648001\">",
"    <span class=\"h2\">",
"     Peripheral blood",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060077\">",
"    <span class=\"h3\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral blood of patients with SS is characterized by a large number of atypical mononuclear cells with moderately to highly grooved (ie, cerebriform) nuclei, termed S&eacute;zary cells (",
"    <a class=\"graphic graphic_picture graphicRef75793 \" href=\"UTD.htm?10/56/11137\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70592 \" href=\"UTD.htm?27/18/27936\">",
"     picture 6",
"    </a>",
"    ). S&eacute;zary cells are best demonstrated on a buffy coat preparation of the peripheral blood, also called a &ldquo;S&eacute;zary cell&rdquo; prep. Typical S&eacute;zary cells are larger than the size of a normal resting lymphocyte (approximately the same size as a normal monocyte) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/41\">",
"     41",
"    </a>",
"    ]. However, a subset of patients demonstrates a smaller variant of S&eacute;zary cells that are approximately the size of a resting lymphocyte. Both typical and small S&eacute;zary cells have a high nuclear to cytoplasmic ratio and a highly involuted or grooved nucleus.",
"   </p>",
"   <p>",
"    The cerebriform nuclear morphology that characterizes S&eacute;zary cells is not specific for neoplastic T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/41\">",
"     41",
"    </a>",
"    ]. Small numbers of S&eacute;zary cells can be observed in the peripheral blood of healthy individuals or those with other benign or malignant diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S&eacute;zary cell counts are subjective and there is considerable inter-observer variability. However, they are relatively inexpensive and may be useful in clinical practice, especially if all assessments are performed by the same reader. S&eacute;zary cell counts are usually reported as a percentage of lymphocytes examined, so to get a total S&eacute;zary cell count, the percentage S&eacute;zary cells must be multiplied by the absolute lymphocyte count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060227\">",
"    <span class=\"h3\">",
"     Flow cytometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flow cytometry of T cell subsets in the blood provides an objective, quantifiable and reproducible means of identifying and tracking blood involvement in SS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Using a limited number of antibodies and duplicate staining, flow cytometry may help to define subsets of lymphocytes that are highly correlated with blood tumor burden. The subsets CD4+CD7- and CD4+CD26- subsets are the most commonly utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The loss of CD26 on CD4+ cells is seen in greater than 90 percent of SS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/44\">",
"     44",
"    </a>",
"    ] and counts have shown prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/47\">",
"     47",
"    </a>",
"    ]. However, the loss of CD7 or CD26 is not distinctive for malignant T cells: they can be seen with aging and with antigenic stimulation and are seen in a small population of normal CD4+ cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/42\">",
"     42",
"    </a>",
"    ]. There has been correlation of CD4+CD26- counts and morphologically identifiable tumor cells in the blood in at least one published study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/44\">",
"     44",
"    </a>",
"    ], but in many cases there may be discordance between the number of S&eacute;zary cells identified by peripheral smear cytology and the number of atypical lymphocytes with abnormal phenotype identified by flow cytometry.",
"   </p>",
"   <p>",
"    Flow cytometry is the preferred method for following patients on therapy or in trials. While it more expensive than serial S&eacute;zary cell counts, the methodology is standardized and less subjective. The percentage of the lymphocyte population or absolute count of CD4+CD7-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CD4+CD26- T cells can be used to determine B status for staging purposes and for assessment of response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/42\">",
"     42",
"    </a>",
"    ]. A normal number of CD4 cells that display the CD4+CD7- and CD4+CD26- phenotype by flow cytometry is &lt;15 percent or &lt;250",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and, if present, would be indicative of a B0 status in the blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060235\">",
"    <span class=\"h3\">",
"     TCR gene rearrangement clonality",
"    </span>",
"    &nbsp;&mdash;&nbsp;TCR gene rearrangement clonality of the neoplastic lymphocytes in the blood is important to confirm the relationship of any abnormal population of cells to the skin lymphoma. The clone should match that in the skin, keeping in mind, however, that more than one clonal rearrangement may be found if more than one biopsy is performed at two anatomically distinct skin sites [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449462785\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10118606\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;SS should be considered in any patient presenting with erythroderma, regardless of underlying or preceding skin conditions that in themselves can cause erythroderma. The initial evaluation includes a biopsy of involved skin with assessment of the morphology, immunophenotype, and clonality (T cell receptor gene rearrangement status) of cellular infiltrates. If the findings on skin biopsy are suggestive of a cutaneous T cell lymphoma, evaluation of the peripheral blood with a peripheral smear, flow cytometry, and clonality studies can help to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10118634\">",
"    <span class=\"h2\">",
"     Site of biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is always best to biopsy the most indurated area of skin. If more than one type of lesion (eg, confluent patchy erythema and follicular-based papules or livido-like erythema) is present, a biopsy of each representative type of lesion should be performed. This helps to determine both the extent of involvement and identifies certain prognostic factors, such as folliculotropism. Because the skin infiltrate in SS is generally much less dense than that of plaque stage mycosis fungoides, it is important to minimize any interventions that could affect the infiltrate prior to taking the biopsy: these include topical or systemic corticosteroids and any other immunosuppressive medication. In general the patient should be off of these agents, especially topical steroids, for at least 14 days prior to skin biopsy to help maximize the potential for a firm diagnosis. A minimum of a 4 mm punch biopsy is recommended. In most cases, biopsies can be placed in formalin prior to hematoxylin and eosin staining and any additional pathology tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10118613\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SS is made based upon a pathologic evaluation of the peripheral blood and skin interpreted within the clinical context. The specific criteria used for the diagnosis of SS are helpful not only for research purposes but also in the determination of the treatment of patients with this condition. The International Society for Cutaneous Lymphoma (ISCL), European Organization of Research and Treatment of Cancer (EORTC), and United States Cutaneous Lymphoma Consortium (USCLC) have grappled with a standardized definition of SS under expanding knowledge about this disease. We agree with the consensus criteria published in 2007, which require the following [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythroderma defined as erythema covering at least 80 percent body surface area",
"     </li>",
"     <li>",
"      A clonal TCR rearrangement in the blood identified by PCR or southern blot analysis",
"     </li>",
"     <li>",
"      An absolute S&eacute;zary cell count of at least 1000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"      one of the following two criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increased CD4+ or CD3+ cells with a CD4 to CD8 ratio of 10 or more",
"     </li>",
"     <li>",
"      Increased CD4+ cells with an abnormal phenotype (such as a CD4+CD7- ratio &ge;40 percent or a CD4+CD26- ratio &ge;30 percent) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is equivalent to the T",
"    <sub>",
"     4",
"    </sub>",
"    (erythroderma) plus B",
"    <sub>",
"     2",
"    </sub>",
"    designation in the TNMB classification syndrome for mycosis fungoides (",
"    <a class=\"graphic graphic_table graphicRef75768 \" href=\"UTD.htm?11/34/11822\">",
"     table 1",
"    </a>",
"    ). Since publication of this revision, blood involvement in",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    (B",
"    <sub>",
"     2",
"    </sub>",
"    ) has been defined further to include absolute number of neoplastic cells identified by flow cytometry (ie, &gt;1000",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    CD4+CD7- or CD4+CD26- lymphocytes) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/42\">",
"     42",
"    </a>",
"    ]. For S&eacute;zary cells, B",
"    <sub>",
"     0",
"    </sub>",
"    is still defined as &le;5 percent S&eacute;zary",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    as proposed in 1979 by the MF Cooperative Group, but B",
"    <sub>",
"     0",
"    </sub>",
"    is also defined as &lt;250 S&eacute;zary",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    to allow the same unit measurement to be used for B",
"    <sub>",
"     0",
"    </sub>",
"    , B",
"    <sub>",
"     1",
"    </sub>",
"    and B",
"    <sub>",
"     2",
"    </sub>",
"    . When blood involvement is identified using flow cytometry, B",
"    <sub>",
"     0",
"    </sub>",
"    may also be defined as",
"    <span class=\"nowrap\">",
"     &lt;250/microL",
"    </span>",
"    or &lt;15 percent CD4+CD7- or CD4+CD26- cells. All of the definitions of B",
"    <sub>",
"     0",
"    </sub>",
"    are in line with normal values in the blood.",
"   </p>",
"   <p>",
"    A representative skin biopsy demonstrating histologic changes that are suggestive of mycosis fungoides (MF) is supportive of the diagnosis. At a minimum, there should be a dermal lymphocytic infiltrate with atypical cells and exocytosis of lymphocytes into the epidermis. Immunophenotyping showing a CD4+ or CD8+ predominant infiltrate with deletion of CD7",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CD5 would be supportive of the diagnosis. Analysis of the peripheral blood by either S&eacute;zary cell prep or flow cytometric analysis should identify a significant abnormal population of lymphocytes. The diagnosis is also supported by the identification of the same clonal T cell receptor (TCR) gene rearrangement in the skin and blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449462806\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SS typically presents with generalized erythroderma and circulating S&eacute;zary cells in the peripheral blood. The differential diagnosis includes erythrodermic mycosis fungoides, other primary cutaneous disorders that may present with erythroderma, drug eruption, and other lymphoproliferative or hematologic malignancies that have circulating T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63648246\">",
"    <span class=\"h2\">",
"     Mycosis fungoides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with erythrodermic mycosis fungoides (MF) may have varying degrees of blood involvement.",
"    <strong>",
"    </strong>",
"    The diagnosis of SS specifically requires that patients that meet the criteria of MF in the skin also meet the criteria of B",
"    <sub>",
"     2",
"    </sub>",
"    involvement as described above. (See",
"    <a class=\"local\" href=\"#H10118613\">",
"     'Diagnostic criteria'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060516\">",
"    <span class=\"h2\">",
"     Primary skin disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060681\">",
"    <span class=\"h3\">",
"     Psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not as common today as in the pre-biologic medication era, psoriatic erythroderma still occurs, and given the common nature of psoriasis, erythrodermic",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    may also occur in patients with psoriasis. There may be clinical clues to distinguish psoriasis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nails in psoriasis may show the typical pitting or oil spots that are not seen in",
"      <span class=\"nowrap\">",
"       MF/SS",
"      </span>",
"     </li>",
"     <li>",
"      Relative sparing of the face",
"     </li>",
"     <li>",
"      Scattered pustules and distribution of any plaques over joints or in areas of trauma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Histologically, psoriasis will typically show psoriasiform epidermal hyperplasia characterized by acanthosis with elongation of the rete ridges and a reactive, primarily perivascular CD4+ lymphocytic dermal infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/49\">",
"     49",
"    </a>",
"    ], all findings that can also be seen in",
"    <span class=\"nowrap\">",
"     MF/SS.",
"    </span>",
"    However, typical neutrophilic collections in the upper epidermis are not seen in",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    unless there is impetiginization. Absence of both CD7 and CD5 expression on atypical appearing lymphocytes and any folliculotropism are features of",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    not typical of psoriasis. Clonality of the T cell receptor (TCR) gene rearrangement can be seen in either condition and is not diagnostic of",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    in the absence of other typical histological findings. The blood in patients with psoriasis will typically not have a significant population of abnormal lymphocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Erythrodermic psoriasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060537\">",
"    <span class=\"h3\">",
"     Pityriasis rubra pilaris",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like erythrodermic",
"    <span class=\"nowrap\">",
"     MF/SS,",
"    </span>",
"    pityriasis rubra pilaris (PRP) can demonstrate widespread areas of erythema and scale, including the scalp; however, in PRP there are usually &ldquo;islands&rdquo; of sparing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Follicular hyperkeratosis with a &ldquo;nutmeg grater&rdquo;-like texture can mimic follicular",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    but is in an atypical distribution (ie, over the dorsum of the hands, knees, and elbows). Nails may be thickened and dystrophic as with SS. Keratoderma may occur, but it is a waxy orange-red color that is distinct from the keratoderma of",
"    <span class=\"nowrap\">",
"     MF/SS.",
"    </span>",
"    Pruritus and burning are common symptoms. The histology of PRP typically displays a psoriasiform dermatitis with irregular hyperkeratosis, perivascular lymphohistiocytic infiltrate, alternating vertical and horizontal ortho and parakeratosis, and follicular plugging with shoulder parakeratosis. The biopsy would not be expected to show all the immunophenotypic features of MF, nor would the blood involvement typical of SS be present unless the entire picture is in fact representative of PRP-like",
"    <span class=\"nowrap\">",
"     MF/SS.",
"    </span>",
"    &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060544\">",
"    <span class=\"h3\">",
"     Atopic dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both atopic dermatitis and",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    can present with erythroderma. Also, it is not unusual, given the frequency of atopic dermatitis in the general population, to find patients with",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    that have both disorders. Lichenification and prurigo nodularis are common in long-standing atopic dermatitis, as is eyelid involvement, but otherwise there are no typical skin-associated findings that can help to suggest atopic dermatitis versus",
"    <span class=\"nowrap\">",
"     MF/SS.",
"    </span>",
"    Both eczema and",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    can be accompanied by eosinophilia in the blood and tissue, although it would be unlikely that patients with atopic dermatitis would meet the criteria for B2 in the blood. Lymphadenopathy may be seen in",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    and in patients with atopy and hyper IgE. On skin biopsy, atopic dermatitis has spongiosis as a primary finding, and this can be a helpful clue since the histologic criteria for patch stage MF specifically excludes significant spongiosis. Finding a CD4+ infiltrate and a clonal TCR rearrangement does not exclude atopic dermatitis as a cause of the erythroderma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060551\">",
"    <span class=\"h3\">",
"     Contact dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic contact dermatitis can mimic erythrodermic",
"    <span class=\"nowrap\">",
"     MF/SS.",
"    </span>",
"    This can be a reaction to a topical application (eg, fragrance), exposure to an allergen that is in contact with widespread body areas (eg, fabric softener), systemic exposure to chemicals that are cross reactive with another agent of which the patient has prior contact allergy (eg, ingestion of cashews in someone with allergic reaction to poison ivy), or a generalized photoallergic dermatitis (eg, compositae). Clinically, the distribution of the rash may help to direct one to a particular type of reaction. These patients do not typically have alopecia, nail changes, or keratoderma, such as can be seen with some cases of",
"    <span class=\"nowrap\">",
"     MF/SS.",
"    </span>",
"    Histologic changes may be similar to those seen with eczema. Patch testing, which could help reveal the inciting agent, is impossible when the patient is erythrodermic. Systemic steroids may be needed to quiet the rash to a point that patch testing is possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=see_link\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060558\">",
"    <span class=\"h3\">",
"     Chronic actinic dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic actinic dermatitis (formerly persistent light reaction, actinic reticuloid) can present with erythroderma. To make this diagnosis, three criteria must be fulfilled:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent eczematous eruption",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      papules and plaques, predominantly on exposed skin.",
"     </li>",
"     <li>",
"      Histological findings compatible with chronic eczema, although changes suggestive of MF may be present.",
"     </li>",
"     <li>",
"      Reduction in minimal erythema dose to ultraviolet B on normal skin and possibly a change to longer wavelength ultraviolet light (UVL) as well [",
"      <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic actinic dermatitis may follow photoallergy to topical agents, which then becomes more generalized and persistent. There may be some clinical clues as to the UVL relationship, such as sparing of finger webs, upper eyelids, behind the ears, and inside skin creases. Histologically, this can be very difficult to distinguish from MF and SS, although there is a tendency for the infiltrate to be more CD8 than CD4 positive [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, there have been reports of up to 20 percent CD8+ S&eacute;zary cells in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/54\">",
"     54",
"    </a>",
"    ]. UVB phototesting is mandatory, as is patch and photopatch testing, all of which can be difficult in the face of an erythrodermic reaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link&amp;anchor=H12594781#H12594781\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Chronic actinic dermatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060566\">",
"    <span class=\"h3\">",
"     Scabies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse crusted scabies, formerly termed &ldquo;Norwegian&rdquo; scabies, can mimic erythrodermic",
"    <span class=\"nowrap\">",
"     MF/SS",
"    </span>",
"    clinically in its skin presentation, including the presence of dystrophic nails and intense pruritus. Histologic changes can be similar to eczema, except where one is fortunate enough to find signs of the mite, including the mite itself, eggs, or scybala (feces). A scabies prep in multiple areas of the body is usually diagnostic, and a trial of antiscabietic medications can differentiate the two conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link&amp;anchor=H9#H9\">",
"     \"Scabies\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060574\">",
"    <span class=\"h3\">",
"     Drug eruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of drug eruptions that can mimic SS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An erythrodermic reaction to a drug that may mimic SS clinically, but on histology typically shows a perivascular lymphohistiocytic infiltrate with eosinophils and a lichenoid vacuolar degeneration that is different from",
"      <span class=\"nowrap\">",
"       MF/SS.",
"      </span>",
"     </li>",
"     <li>",
"      A",
"      <span class=\"nowrap\">",
"       MF/SS",
"      </span>",
"      mimicker, both clinically and histologically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drugs should always be considered in the differential of",
"    <span class=\"nowrap\">",
"     MF/SS,",
"    </span>",
"    and an attempt should be made to stop potentially offending drugs and to avoid substitution of any from a similar class of drugs for at least two months to see if the rash will resolve. In addition, the biologic agents or immunosuppressive agents that are used to treat psoriasis and a variety of autoimmune disorders can induce a lymphoma, including one that mimics",
"    <span class=\"nowrap\">",
"     MF/SS:",
"    </span>",
"    a trial off of the potential offending drug should be performed before initiating directed therapy for the lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060861\">",
"    <span class=\"h3\">",
"     Graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft-versus-host disease (GVHD) typically occurs in patients who have undergone an allogeneic hematopoietic cell transplantation where immune competent cells from an allogeneic donor participate in an immune attack on the skin and other host tissues. It rarely occurs following solid organ transplantation or in other settings where an immune incompetent person receives an infusion of immune competent cells that result in a T cell targeted attack. Acute GVHD may be associated with a widespread erythematous rash or erythroderma. The skin biopsy may reveal dermal lymphocytes with varying degrees of dyskeratosis of epidermal cells. The clinical setting and the associated findings of lung, liver, ocular, and GI disease can usually help distinguish this condition from SS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060581\">",
"    <span class=\"h3\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large percentage of erythrodermas may defy an exact diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. Many of these later turn out to have MF or SS, although at presentation they do not meet diagnostic criteria. Erythroderma can also be a nonspecific finding of an underlying systemic B or T cell lymphoma. The histologic findings are nonspecific. At a minimum, a chest radiograph should be performed. If peripheral adenopathy is present, a computed tomography (CT) scan should be performed in addition to biopsy of a representative lymph node. Any patient with erythroderma without a definitive diagnosis should be followed closely and repeat biopsies of skin or biopsy of any new enlarged lymph node performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060589\">",
"    <span class=\"h2\">",
"     Other lymphoproliferative or hematologic diseases",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521128978\">",
"    <span class=\"h3\">",
"     Adult T cell leukemia lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult T cell leukemia lymphoma (ATL) can be difficult to distinguish from",
"    <span class=\"nowrap\">",
"     MF/SS.",
"    </span>",
"    Both of these disorders share a similar skin and immunophenotypic picture, although ATL has a more uniform, strong positivity for CD25. ATL, however, is much more likely to have disseminated extracutaneous disease with frequent lymphoma in the nodes, liver, bone, and central nervous system. A key differentiating feature is the presence of HTLV-I in the malignant cells of ATL, which can be determined by testing for the antibody in the blood. ATL is common in Japan and the Caribbean and is unusual in mainland USA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521129025\">",
"    <span class=\"h3\">",
"     T cell prolymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both T cell prolymphocytic leukemia (T-PLL) and SS are T cell neoplasms that can involve the blood and skin. The morphology of the \"cerebriform\" (S&eacute;zary cell-like) variant seen in 5 percent of patients with T-PLL resembles the S&eacute;zary cells seen in SS. In such cases, SS can be distinguished from T-PLL by the immunophenotype. S&eacute;zary cells typically lack expression for CD2, CD3, CD5,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CD7. In contrast, T-PLL cells have strong expression of CD52 and typically express CD2, CD3, and CD7. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10102?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060612\">",
"    <span class=\"h3\">",
"     Hypereosinophilic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythroderma can also be seen in patients with the idiopathic hypereosinophilic syndrome, some of whom have a clonal proliferation of T cells with increased production of Th2 cytokines that may evolve into lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/59\">",
"     59",
"    </a>",
"    ] and abnormal T cell clones [",
"    <a class=\"abstract\" href=\"UTD.htm?9/31/9722/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Skin disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20591927\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with S&eacute;zary syndrome is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4713?source=see_link&amp;anchor=H1118942#H1118942\">",
"     \"Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome\", section on 'Stages IVA and IVB'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449464055\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S&eacute;zary syndrome is an aggressive leukemic variant of cutaneous T cell lymphoma (CTCL) in which a significant number of circulating malignant (S&eacute;zary) cells are observed in the peripheral blood.",
"     </li>",
"     <li>",
"      S&eacute;zary syndrome is thought to be derived from mature epidermotropic skin homing CD4 positive T cells or central memory T cells. Cytokines have been implicated in the pathophysiology of S&eacute;zary syndrome, but whether cytokine abnormalities are primarily involved or are secondary processes in the pathogenesis is unclear. (See",
"      <a class=\"local\" href=\"#H449461398\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with S&eacute;zary syndrome commonly present with erythroderma and generalized lymphadenopathy developing over weeks to months. The skin is often pruritic and the patient's quality of life is profoundly affected. Other common clinical manifestations include opportunistic infections, alopecia, keratoderma, and, less commonly, involvement of other organs. (See",
"      <a class=\"local\" href=\"#H449461426\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of a patient suspected of having S&eacute;zary syndrome should include a biopsy of erythrodermic skin, examination of the peripheral smear for S&eacute;zary cells, flow cytometry of the peripheral blood, and an analysis of T cell receptor (TCR) gene rearrangement by polymerase chain reaction (PCR) or southern blot analysis. (See",
"      <a class=\"local\" href=\"#H449462785\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      S&eacute;zary syndrome is a clinicopathologic diagnosis based upon the presence of the following three criteria (see",
"      <a class=\"local\" href=\"#H449462785\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Erythroderma defined as erythema covering at least 80 percent body surface area (see",
"      <a class=\"local\" href=\"#H449462700\">",
"       'Skin lesions'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      A clonal TCR rearrangement in the blood identified by PCR or southern blot analysis",
"     </li>",
"     <li>",
"      An absolute S&eacute;zary cell count of at least 1000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"      specific findings on immunophenotype (see",
"      <a class=\"local\" href=\"#H63648001\">",
"       'Peripheral blood'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S&eacute;zary syndrome is equivalent to the T",
"      <sub>",
"       4",
"      </sub>",
"      (erythroderma) plus B",
"      <sub>",
"       2",
"      </sub>",
"      (&ge;1000 S&eacute;zary",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      designation in the TNMB classification syndrome for mycosis fungoides (",
"      <a class=\"graphic graphic_table graphicRef75768 \" href=\"UTD.htm?11/34/11822\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4713?source=see_link\">",
"       \"Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/1\">",
"      Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/2\">",
"      Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/3\">",
"      Olsen EA, Rook AH, Zic J, et al. S&eacute;zary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 2011; 64:352.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/5\">",
"      Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/6\">",
"      Introcaso CE, Hess SD, Kamoun M, et al. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with S&eacute;zary syndrome. J Am Acad Dermatol 2005; 53:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/7\">",
"      Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/8\">",
"      Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/9\">",
"      Clark RA. Regulation gone wrong: a subset of S&eacute;zary patients have malignant regulatory T cells. J Invest Dermatol 2009; 129:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/10\">",
"      Gibson HM, Mishra A, Chan DV, et al. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for S&eacute;zary syndrome. J Invest Dermatol 2013; 133:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/11\">",
"      Yawalkar N, Ferenczi K, Jones DA, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003; 102:4059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/12\">",
"      Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 2011; 155:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/13\">",
"      Contassot E, French LE. Targeting apoptosis defects in cutaneous T-cell lymphoma. J Invest Dermatol 2009; 129:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/14\">",
"      Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 2011; 147:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/15\">",
"      Kari L, Loboda A, Nebozhyn M, et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003; 197:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/16\">",
"      Curiel-Lewandrowski C, Yamasaki H, Si CP, et al. Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma. J Clin Invest 2011; 121:4838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/17\">",
"      Nebozhyn M, Loboda A, Kari L, et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 2006; 107:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/18\">",
"      Ballabio E, Mitchell T, van Kester MS, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 2010; 116:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/19\">",
"      Laharanne E, Oumouhou N, Bonnet F, et al. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol 2010; 130:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/20\">",
"      Lee CS, Ungewickell A, Bhaduri A, et al. Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Blood 2012; 120:3288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/21\">",
"      Karenko L, K&auml;hk&ouml;nen M, Hyytinen ER, et al. Notable losses at specific regions of chromosomes 10q and 13q in the S&eacute;zary syndrome detected by comparative genomic hybridization. J Invest Dermatol 1999; 112:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/22\">",
"      Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in S&eacute;zary syndrome and mycosis fungoides. Br J Dermatol 2002; 147:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/23\">",
"      Fischer TC, Gellrich S, Muche JM, et al. Genomic aberrations and survival in cutaneous T cell lymphomas. J Invest Dermatol 2004; 122:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/24\">",
"      van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009; 113:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/25\">",
"      Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113:5064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/26\">",
"      Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007; 143:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/27\">",
"      Saunes M, Nilsen TI, Johannesen TB. Incidence of primary cutaneous T-cell lymphoma in Norway. Br J Dermatol 2009; 160:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/28\">",
"      Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006; 107:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/29\">",
"      Sausville EA, Eddy JL, Makuch RW, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the S&eacute;zary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1988; 109:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/30\">",
"      Beylot-Barry M, Parrens M, Delaunay M, et al. Is bone marrow biopsy necessary in patients with mycosis fungoides and S&eacute;zary syndrome? A histological and molecular study at diagnosis and during follow-up. Br J Dermatol 2005; 152:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/31\">",
"      Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol 2012; 51:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/32\">",
"      Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and S&eacute;zary syndrome. Br J Dermatol 2008; 159:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/33\">",
"      Lee J, Richardson SK, Melhem ER, et al. Progressive multifocal leukoencephalopathy from JC virus in a patient with advanced mycosis fungoides. J Am Acad Dermatol 2007; 57:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/34\">",
"      Huang KP, Weinstock MA, Clarke CA, et al. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol 2007; 143:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/35\">",
"      Herro E, Dicaudo DJ, Davis MD, et al. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic. J Am Acad Dermatol 2009; 61:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/36\">",
"      Olsen EA, Delzell E, Jegasothy BV. Second malignancies in cutaneous T cell lymphoma. J Am Acad Dermatol 1984; 10:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/37\">",
"      Vonderheid EC. On the diagnosis of erythrodermic cutaneous T-cell lymphoma. J Cutan Pathol 2006; 33 Suppl 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/38\">",
"      Guitart J, Magro C. Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones. Arch Dermatol 2007; 143:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/39\">",
"      Guitart J. Beyond clonal detection: defining the T-cell clone. Arch Dermatol 2005; 141:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/40\">",
"      Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/41\">",
"      Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/42\">",
"      Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S&eacute;zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29:2598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/43\">",
"      Nagler AR, Samimi S, Schaffer A, et al. Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of S&eacute;zary syndrome. J Am Acad Dermatol 2012; 66:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/44\">",
"      Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+ CD26- subset in the identification of circulating S&eacute;zary cells. Br J Dermatol 2001; 144:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/45\">",
"      Bogen SA, Pelley D, Charif M, et al. Immunophenotypic identification of Sezary cells in peripheral blood. Am J Clin Pathol 1996; 106:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/46\">",
"      Jones D, Dang NH, Duvic M, et al. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001; 115:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/47\">",
"      Vonderheid EC, Pena J, Nowell P. S&eacute;zary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging. Leuk Lymphoma 2006; 47:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/48\">",
"      Vega F, Luthra R, Medeiros LJ, et al. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood 2002; 100:3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/49\">",
"      Tomasini C, Aloi F, Solaroli C, Pippione M. Psoriatic erythroderma: a histopathologic study of forty-five patients. Dermatology 1997; 194:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/50\">",
"      Clayton BD, Jorizzo JL, Hitchcock MG, et al. Adult pityriasis rubra pilaris: a 10-year case series. J Am Acad Dermatol 1997; 36:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/51\">",
"      Albert MR, Mackool BT. Pityriasis rubra pilaris. Int J Dermatol 1999; 38:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/52\">",
"      Hawk JL, Magnus IA. Chronic actinic dermatitis--an idiopathic photosensitivity syndrome including actinic reticuloid and photosensitive eczema [proceedings]. Br J Dermatol 1979; 101 Suppl 17:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/53\">",
"      Leenutaphong V, von Kries R, H&ouml;lzle E, Plewig G. Solar urticaria induced by visible light and inhibited by UVA. Photodermatol 1988; 5:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/54\">",
"      Chu AC, Robinson D, Hawk JL, et al. Immunologic differentiation of the S&eacute;zary syndrome due to cutaneous T-cell lymphoma and chronic actinic dermatitis. J Invest Dermatol 1986; 86:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/55\">",
"      Zip C, Murray S, Walsh NM. The specificity of histopathology in erythroderma. J Cutan Pathol 1993; 20:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/56\">",
"      Sigurdsson V, Toonstra J, van Vloten WA. Idiopathic erythroderma: a follow-up study of 28 patients. Dermatology 1997; 194:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/57\">",
"      Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the \"red man\". Clin Dermatol 2005; 23:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/58\">",
"      Botella-Estrada R, Sanmart&iacute;n O, Oliver V, et al. Erythroderma. A clinicopathological study of 56 cases. Arch Dermatol 1994; 130:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/59\">",
"      Gotlib J, Cools J, Malone JM 3rd, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/60\">",
"      Simon HU, Pl&ouml;tz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/31/9722/abstract/61\">",
"      Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59:673.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16193 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-8FC26C7E2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9722=[""].join("\n");
var outline_f9_31_9722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H449464055\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H449460985\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H449461398\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H449461419\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H449461426\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1059750\">",
"      Signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H449462700\">",
"      - Skin lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1059786\">",
"      - Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1059795\">",
"      - Viscera",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1059823\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1059831\">",
"      - Pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1059838\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63648088\">",
"      - Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H449462735\">",
"      - Second malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H449462742\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1059997\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060012\">",
"      - Light microscopic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060880\">",
"      - Clonality of the T cell receptor (TCR) gene rearrangement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060895\">",
"      - Immunophenotyping confirming T cell origin (CD3+, CD4+)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060019\">",
"      Lymph node biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63648001\">",
"      Peripheral blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060077\">",
"      - Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060227\">",
"      - Flow cytometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060235\">",
"      - TCR gene rearrangement clonality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H449462785\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10118606\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10118634\">",
"      Site of biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10118613\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H449462806\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63648246\">",
"      Mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060516\">",
"      Primary skin disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060681\">",
"      - Psoriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060537\">",
"      - Pityriasis rubra pilaris",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060544\">",
"      - Atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060551\">",
"      - Contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060558\">",
"      - Chronic actinic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060566\">",
"      - Scabies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060574\">",
"      - Drug eruption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060861\">",
"      - Graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060581\">",
"      - Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060589\">",
"      Other lymphoproliferative or hematologic diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H521128978\">",
"      - Adult T cell leukemia lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H521129025\">",
"      - T cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060612\">",
"      - Hypereosinophilic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20591927\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H449464055\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/16193\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16193|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/30/11745\" title=\"picture 1\">",
"      Erythroderma in Sezary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/54/12128\" title=\"picture 2\">",
"      Follicular involvement in MF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/9/9375\" title=\"picture 3A\">",
"      Diffuse alopecia in SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/38/8806\" title=\"picture 3B\">",
"      Localized alopecia in follicular MF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/32/11783\" title=\"picture 4\">",
"      Keratoderma in S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/56/11137\" title=\"picture 5\">",
"      Sezary cells mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/18/27936\" title=\"picture 6\">",
"      Mycosis fungoides blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16193|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/34/11822\" title=\"table 1\">",
"      Mycosis fungoides TNMB classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=related_link\">",
"      Clinical features and diagnosis of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10102?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4713?source=related_link\">",
"      Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=related_link\">",
"      Treatment of early stage (IA to IIA) mycosis fungoides",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_31_9723="Presenting symptoms gastric CA";
var content_f9_31_9723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Presenting symptoms of gastric cancer in 18,363 patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysphagia",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melena",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early satiety",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcer-type pain",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Wanebo, HJ, Kennedy, BJ, Chmiel, J, et al, Ann Surg 1993; 218:583.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9723=[""].join("\n");
var outline_f9_31_9723=null;
var title_f9_31_9724="Lung disease in IBD";
var content_f9_31_9724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pulmonary involvement in inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Patterns of involvement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of total",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Respiratory",
"disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchiectasis",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic",
"bronchitis",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Interstitial lung disease",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchiolitis",
"obliterans with organizing pneumonia",
"(BOOP)",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic bronchial suppuration",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subglottic",
"stenosis",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Necrobiotic nodules - neutrophilic",
"infiltrates",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic bronchiolitis",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary",
"infiltrates with eosinophilia",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Serositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pericarditis",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pleuropericarditis",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myocarditis",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pleural",
"effusion",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Patterns of lung disease in patients with inflammatory bowel disease: 89 patients had respiratory involvement and 42 patients had serosal disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Camus, P, Piard, F, Ashcroft, T, et al, Medicine 1993; 72:151.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9724=[""].join("\n");
var outline_f9_31_9724=null;
var title_f9_31_9725="Diagnostic studies in IPH";
var content_f9_31_9725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Principal and ancillary diagnostic studies in idiopathic pulmonary hemosiderosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          General diagnostic studies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary function tests including DLCO",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          High resolution CT-scanning (HRCT) of thorax",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary perfusion and ventilation scintigraphy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary radioscintigraphy with radio-labeled RBCs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sputum examination for hemosiderin-laden macrophages",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Screening for coagulation defects",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma immunoglobulins (IgG, IgA, IgM, lgE)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma antinuclear antibodies (ANA)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma antidouble stranded DNA antibodies (anti-dsDNA)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma antineutrophil cytoplasmic antibodies (ANCA)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma antiglomerular basement membrane antibodies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma antiphospholipid antibodies (IgG, IgA)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma rheumatoid factors (IgA, IgM)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma IgA anti tissue transglutaminase and endomysial antibodies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma antireticulin antibodies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma anticow's milk antibodies (IgG, IgE)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma cryoglobulins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma complement levels",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Blood eosinophils",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Urine analysis for protein, hemoglobin, RBC casts",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Skin prick test with appropriate antigens",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Evaluation for anemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Erythrocyte indices",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Serum transferrin saturation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Serum ferritin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Plasma cobalamine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Erythrocyte folate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tests for hemolysis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tests for hemoglobinopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Examination for gastrointestinal, urinary, genital tract bleeding",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bone marrow biopsy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Flexible fiberoptic bronchoscopy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bronchoalveolar lavage",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Transbronchial forceps lung biopsy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Lung biopsy for",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Light microscopy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Perl's Prussian blue stain",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Immunofluorescence or immunohistochemistry",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Electron microscopy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          In selected patients",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Skin biopsy (leukocytoclastic vasculitis)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Jejunal biopsy (celiac disease)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Renal biopsy (glomerulonephritis)",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9725=[""].join("\n");
var outline_f9_31_9725=null;
var title_f9_31_9726="Proximal solute gradients";
var content_f9_31_9726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solute concentrations along the proximal tubule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 243px; height: 238px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in tubular fluid composition along the length of the proximal tubule. For solutes, the lines represent the solute concentration as a percent of that present in the glomerular filtrate. In comparison, the line for H2O represents the percent of the filtered load remaining in the tubule. Some solutes, such as bicarbonate, glucose, and amino acids, are almost entirely reabsorbed in the early proximal tubule, resulting in a marked reduction in their tubular fluid concentrations. Sodium, on the other hand, is reabsorbed to the same degree as water, so that there is no change in the sodium concentration as fluid moves down the proximal tubule. However, the preferential reabsorption in the early proximal tubule of sodium with bicarbonate and glucose has an important secondary effect: the ensuing passive reabsorption of water leads to a",
"    <strong>",
"     rise in the tubular fluid chloride concentration",
"    </strong>",
"    above that in the plasma. This chloride gradient is sufficient to drive passive sodium chloride reabsorption in the later aspects of the proximal tubule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Rector, FC Jr, Am J Physiol 1983; 244:F461, and Maddox, DA, Gennari, JF, Am J Physiol 1987; 252:F573.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9726=[""].join("\n");
var outline_f9_31_9726=null;
var title_f9_31_9727="ERCP in chronic pancreatitis";
var content_f9_31_9727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ERCP in chronic pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 248px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD4AWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1vYScAmp7e0YnMmQPfvWhFbrEST8znvUjdeeaAFt3AQQtzHjg96hnt2RyM5B6U/OMZOKsowaIluSlAFGeMIgXd9arthV3P8voPWlu7nk4+961k3EjNuyxOe9AEl3qDcrEce/eseTez5ZmJ9c1aZepNRsvPWgCsQSfvHP1pp69TmpmXB/lUbDFADPu88nNRSsRkA1KxJ4Az2qWOzJC7+KAMryzIcKWz9aljsHkyFLZrpbawiSIM+AD+tTZSMbYwPrQBwWu6ZdFcpnCjjB5qz4Rhngi8uUtljnLV0GoLIHPy/L1pbOJfLJJw46UAdTpqRLbL82WHXmnT3AwQvBHTNU9HhMy7ycY4AzWhLasy9ASKAKj3TA/fxUT3R6iQk/SrBt2OVI/SqMtu6seuKALVpcyeaMkkGi9upAdoz061XiVg2ec59aLmPccuQfXmgBn2l8ry2T71bhmckA59ahtrdD/ABA47VrqkcSDPLelAGLqc5KkDj3rnblTJuLE4rq9ZSJ4QwwDXOiLzYSqgdaAOB1q3xKwViBnoDXPXsEqN+7J/A16FqWmncXlAA+tZsGkJcSKMHAPPvQBS8OwSBA0m4n3rrbCFt3AIJ96jtbFYCuB14rvNF0iFII5SuXxnJoAk8N6aY1MkgwSOAetdNDAoHNRWyhFpXnIO0UAPuEJQgdKyp41VTkVpCUFfmPNZmo3axoc9KAOY1WcLJsESsD3Nchqeli6LNG21xzgd66nVpLd4XZQ6v0B7Zrz7U7nVIpysOXQd1H86AOV8S2n2JJJZnY84GD3rg5ruVpCS7fnXYeKJZmhZZcgMcnPY1xMhIJ70AP+0SA/fb86abpweWbH1quz8dKjPztwTQBpRXbHqzfnU6yswBEjfnWVt2Ec5qxE/QjNAGks0gPDN+dXYbiQIWLnAODzzWZG6sRuGD6iptjAE9R6igDQt7tjcLktyw5BoqhZy7btNx43CigD69OQSe1MPqRUp4znpVeaQMcbgPQUARSyhTx1pyz5s5T0+tUpmZWIYGpJyV00cHLGgDLmcsTzxUT9DgVI2c8HigjI6UAQ7eeelQOPmyatEdSPSiO2Z+owKAKeC2B+VL9lZ+W4FaiW6oPU09k9T2oAz4rZExtGW681cgtjI3XkDNKQvRQSasQJ5YzIcUARXPyhQPSqyqMls9KddXUZc7mAUVWF1CzhS+B6CgC2yq6AyD6VEIo0YkDBNNmu4gmS+BSC4ikBw3WgDV0yTybcgHPcfSrIvSejc+lZulkkygDgDilGGfgEUAajXAeMNk56HFUJ3Jb1BqzDGBByTyagu48A4PvQBCjHf6CluCcg44pltywGRUt2jKFbPWgBbVwJAwOaddyyGUgk9aS3XCgkfpUs67gHxmgCleOTEcnmqikLGduBmrbwlo5DjtzWDcSuMgMQPrQBLfeW0fzMPfJqtZSwISV+as+TqQe/XNWrZAkRIxjGelAFyxma7vwkKgYPfpXplgCIFUkHjtXlGkq32wbTg5xxXqen4gtlLNnigC9KwSM1zl/r0VpLtfJOecdq2pZVkQ4YYxXj/i/U/Iv2OCV3HNAHeN4ssQ2GLfWsnXvFFuiEwgyKfeuWtZbC9gDxA7m65PQ1wOs6j9n1CSJJGDq2AQeKAO/h8XRtKyXkA8gDJOeabd65p7xedb4H+yetef8A2jzkw5BJ64qpLLsUhDkCgDe8WXVnqliPKCmReWPevNLu2K7gp/A1sm+ZWZdvB75qhMRIxOcH3oAxWVlbDCmkDqOtajwBgc1Tltyu4rmgCKKTD4YZqwhB5AqmqkHJBzU0RxjOaALiMelWUkZB14PaobZAW3N0FTvh24xQBLaoJZ0HQlh9KKdYIfOT/eFFAH1bcXO5sEkDP5CqErksdrHGePWlYgk/WmbNzYoA0NNcTsEkGR3NaV5bwyRBDjHtWSskcNuURsuepHaqn7wthS3tzQBcl0vnMbZ9jVVrGbfjYfrV60WRE8ySRiueFq/DcBhg4BoAxVtViGX5NSrEWbPRR1rWeCOdxlfqRS3CxRW5DYCigDDYbnwnaopCkK5lbn0plzfohKwD/gVZE7tKdzMSSaALwugckdB6VS1DUW4RDjPFSRRNsIAxmqUlsqSl5X4zQBRuJC0uWboaWPO4OWwo702eSNZGKJuPqarTzlhzx7CgC/POrITvBqSN+FYEj3Nc1NcOH/dtgg1tafdefGqy4EnqOhoA7XQMvZyH16E1bjtsMc45qppp8u0RQMA1Pvc8g4FAFqXCqEBziqb43YpA7F/WiUMwBx+dADbaJftiZ6E1oXkS/ZgepDelUbcMJwT0rQucm2bPegCiGAO0DiniYR8H5gahCkE4NRSRuQOKALLyo6OANoIxxXI3ilJWA6A10YjcA8Vz9/8A69sHp1oAxby6S3fG3dJQuoSOoUgD6Vk6gzfb33cimpNh8cigDsfD8bPMJDwAciuzlmdLdQW69RXCeHrsoEJPHoa6x7yOXaWIAX3oAjvdSks4GkR/qDXifjTXJbnUHTpEDnpXreslbmJghA4xXnfiPRI2hMjIFfs1AHL6Z4h+wRvGCQGHWudurzzrpnOWZjnNTX1iySsBmqcFpIJM7SaANGxnYscZyelLqUzkhVyuOpzUEStHKASRSak7F9xxg+lAFQylCQ4yDQGVuQc+1QOdwqudyk4P60AXWbHSiQgj1qilx/eJqYSAj5TQAuFdSCMmmCHbyMmlQ5Y4qzGRQAyPOcZ4q2iFcGkWEMeMg+orUit45LVSWAlHGD3oAZpqBpk/3hRVmzh2TL9RRQB9GfLk8HrTXb04HoKcBubAySTVuG2CckZagCrFAW5bgH9atrEFGAOlWNmKaRnkUAQnI4J4pYkZnAUmpRCznngVNDPaWr4kkG6gB8s62cO6Q1lTX4u8gjA9Kh1e4W5uWKMTGOFzWcwwOCaAJ7qBdpZOtZfIfBFWzclAAxzmnYR1zQBCzMkWScVjTEybtze/WtS8fEeF6dKx55VUYoArE7W5qvcMADtBz7Uk7sxyDx9aYrE/cGTQBWddyZHBq5piO00fOMU9YsxsSM/hT9KcfaB7etAHd2N5EsCLIo3KOvrVk3ikcAY+lUNKs2niDMVVT3J61pjT8DqDQBUa4YNkHioZrsnqx/OrsliNpBIH41QntkDduKAI1uzuzubP1qzLfkx4xnPqar+QgPQDNStHGFA7UAV1vCwoEkr/ADKcCpVEHoea1IBAIwAgwB3oAxpZ5QuN5GaxNRk8sk966m4uYBwsaknviuQ1qFpZWYcR5oA5jUZA0pIbk+1Vl3HB/SrJhE11sUrge9TTWZibPQdjQBc0y4YKOCDW9HcGSPDNjtWHZuFAHX3xWrGUfGQB70ATKz5CnJUdzVDX4pLi3AUA4HStJUwvyMMe9VZvMDjeD1444oA4iTTzKrI0Y49apy6YYImZVyPUV6MsULqwKjJ4ziqkulqQ3lc8dDQB5LIm2Yl/yqtdQeYuU6V2/iHQmaMyohBHXFcdMjQkqw49KAMSSMxk561XY57VqXQyNwH1rKuFIORQBXdcn0pqsUzzSs9MbJzQBbgk3N1FX4lBI5H41jRttcVq2r5AzQBp26EtnNaltFuYbhwfWqdnGSMg/hWxbDGCetADxaPFIh6rkGittdjQxHI3A4NFAHt0MYQHjn1qXGBxxSAHvUmAMFjz6UAIBkc0jOqDoCaSSUKPSqU0hycHrQAl9duy4U4+lZe4lvmOSanlPvzVZuGyKAFzTXOTimk0wnnHagCG4GZB7VH5ojXriiWTBJY1kXNw7ybQDj2oAmurvecA4qhsZyQvJq5bWTSuGkJA9K0GtlQcLigDHW0/56kdOQKXYFBCLgVoyQjBNQNDsUnHHtQA1Y18jPc1VsIWS5zjPPFWyfMAHTHWr1kkUXzEbmHrQB0GmuRbqG4I6VcF0Vzk5rOtrlWIG3AxwaWZtrHByPWgC7POrJuXr3rKuZgTmrEL/JIT07Vm3gkIyqnB70AK1x836VoIy+SQOQUzmubSTMg8yQIScYzk1rJfQQWjHIJVTyTQAxpWGc9BSXOpLDbOzMWPHArjLzxJJPcYT7hyAKj+2STLIshzuXGKANHU/FPkodiAe4Nc+2vTXgJlfEZ4OTwKw9SSRtwBPFc/eXMyRckgdBigDqIJ4TucTsGJ6irq6t5WFNxvX0YVxEE8iqFTntgU27unjwG4J7ZoA9U0+6ilAO5Vz6mtJcggH8K8gs9bWA5MjH2Brp9L8ZogVJvnj9CeRQB6AjkthiAB0qx5zYAPP4ZrC07WrG8wUuEB/usea3bZo5CMOp/GgB4EchB+6f0qGZ2hbIyw7kVeMaAcsvFV5VXqCPwNAEQkinUq2CD1BrhfF+jLDK0sCDY3Nds0I3crz6iqeqW5MW1/nU9PagDx6cbGwaz7qHcGKd66jxJp5t2LKmVNcw74J54oAxJAVYg5BoXkHmr1zEJRkdRVTZj696AHwplu1aEC7cVTgQ7hWjEBQBoWcxVgCa37WVXAGcGubhTkVq2mVIzQB0Vq+HVWx1oqvaSAum4dxiigD6JA+UkGmSNtGaVmCdevpVK4mLcA0AE0ucjPWq75K5zzQB70NgLQBDIO/wCdV3APGKnfrWhpulNcMHlyE649aAMdLeSU7UVmPtU7aReFCwjP0zzXaW9pHCoVEA+gqbZQB5dNY3Ycq1vJn3BojskiP7xCGx1Ir05kGOlZ+oWMU0Z+QbvWgDg2h24YHjNSMV2ZkOMVl+JdUGj3LQyDLE/KM1zkN/cXt8BLIRGegBoA6K4vYUk5OQO1UbjWbcZAJBHeszUpEtmKk9eetctqWpw4bb8zA+tAHYRa1bCQAygE+tbun3kc4XBUg9wa8WbUHcsqnGBxgVJp+p3ETDypGVyfXrQB9C6dCJEJVhgds1N5PzYdsd65/wAHaoi6SjXH+sxzj1rRbV493mAZUnrQBrfZ1WIhWHrg1k6nOfskkRYKoGR7Uy81FZAQjHOM4FcL4h1u43PGxIjH50AZevX9wkpFrleuWzzS6fqMh0qUbsuFYHJ7kVAszXEZZseoFNcYRlRcKRknFACWMPl7GlIPtmrkcwWUsrdD2rCnuZkAVW/+vU+h295fz7IIZJHz1Hb8aAOinsLa8XejLlhkgnvXH+LbCGzs1fzAzA52Lir2rreafcNDPlHH909K5vU0lkgeRyWGMZ70AcvLrsi/8e/ynoD6VTP2q5jMpkY4OSKZcQBCGJ5ycirVkgEagv8AKxzgUAMgLnr1rRsxKWHUmrBtfMj/AHcZJyMYrptF8PmWxE0gYPnAHegDDV57dhuVkz0rVttbuY+RNICOmDUmvKbcrA/OAME9awnZl6UAdnZeN5osCfLitez8RQXhHlzYY/wk4ryt5PmzToZWVsqSCOlAHuFhrSghJssPU1qmSK5j+U59K8a0vX54AqzfvE9+tdjpOrLMu6GQsp6qeooAu67pplDdvpXnuraW8DMVXpzxXpM8rOoO/wDGuc1RkWcCUjYepoA4IpgdKqumCTW9e2aiRjGRjPasy4gbn5TQBXj4OBV2FSRzTrXTbiVVeOJmU9MVvafo9zKyQpau0rHoBQBnWqktyK1IFI5xXcWHgKVbXdOyeeRnYO1c/qGnG0Zl7qcEUAUoGxIg96KfCpEi59RRQB9AXErMW5qDOBzW0dNQk4B601tKDHqRQBjHr70jMQDWnJpUgJKnNVhYTG4VWHB6n0oAfpdkbiTe4yorpoYgigAUyzt1iiVQOlWgtADcUhqTFNIoAhbpVS8lSGJ3kYKqjJJ7ValO0EmvJviJ4lF8ZtK0+bB5VyO59KAOB+Ieuw6n4jleBgYk+RWHfFN0C9ijgd5WGUHH/wBauL1OCW0ujHKTvHWltZpBImwkj0zQB0mvajJNbyFSck4UCuOVnWU7yff2ruxp3naZ5o6nk1xOqRGOQqB0oAhuZo0hbyzuJ7jrUmiSk3SZ5NZsyuSABToDJDtcMQw7CgD2bTNRs7fS4klnXzz/AAjtWlaSrcKoRm2A9cda8i0ktdzgQuwlz0r0zTYJYLdQ5YEjucUAaOrX8WnQEquXPYmvPdX1d53LyPHyemecVua/BcyLI6ncQOB14rzm6srlpSZGf8RQB6H4PkS7jkZpVyDgA1e1qSEwPHbsQ+DkiuL0fdY6ezrI/mk4x6133hnRm1HTo55c/N60AeVXlzIkhBeTIPc1678OYTbaJFPlj5nzE9+az/FfgVHtnmgiIlH61f8AB+m6pBpaWz8RpwPUCgDmPFYE15czRBid3Gec1xl3cM0JCqQ+a9xm8IL9mkZpCxfJ5xmub8OeAojez3NzMkwjJAjx3oA8PvbaaRiShGeenFU7KJ0ukDZABxX0dc6JbEbJIUGDgDZ2rLufhjp1/O9xYSSxY5KHpmgDkNK8i1tBNJGCy84Falhr6S2jJawAEOSGPatjXfC9za6DJCtokkg6Sq3IH0qj4A0KKXT5Be28gk38hgelAHM62l3dTRvJGXZjxtHGKqapYzmJJBZtEMYbA4r1e6sYkuI4RCAoPygCtQ6XGbQtLCMMOhoA+eJLds9OarjKOeM12njCyjsdTYQqoRhuAHauOlBMrYBFAD4n5x0rT0+6kgkDRsQfUVkKpHrVmF8f/qoA9O8NXi38LrcYTA4YdCa5rxIkyak8LkFR90r3FVdAvJ1lEUCltxGfau8sNJea4MskQkJGcEUAebglOD0Fa9hdWsto1vcRhWPQ+tdnqOj2RyfKAOPmVh0rEnsLQDcVCgDg0AWvDNtaRSbTPx2U16D4Rs7WO5MrEFmGPpXjPlBbo+SxCg8HNb9pf3sWwpK2E5GKAPa9StkWJpIXwo55NeTeKwv9oHYR05HvU83ii/NsITyT3rFnaSdzJJ1J7+tADIl3Fc+ooqeBQNvuaKAPp4Q08RjHSrAUU7aKAKxiHpTVhXOcCrRHtQBQBCFxSkVIR7UmKAIzTG4FSt1qKTgUAcv491b+yPD9zOp/eEbU+pr5rg1aW31Hz2+di2TmvW/ivrUctz9hPKJ/OvGr23w7CLJbrk0AQ+IbpbzUmlXHI5FP0myklIkC/L60ado9xc3SAoShOT9K6uG22gLjCDgKKANDRQiRhJG3KeorK8VeH4x/pMIZkPoK7Hw7oQcrNJyp5CitbXLZI0jj2Ao3DKaAPBWtsyFQpA9T2q02jEQl3OF/vetenz/Dy6vZBNZBY435O/tVj/hXWprbmJ2ikXtg4NAHBeDbNoLiMwKpPJdyM5rtI70SAhgmQO61vaF4PnsLRkZFVyc5qS68PyQlpl2k/TpQBztxdTxt/qkMbDAO2sTT9DvNZuXFuyBVbB+Wt97i7USW91AGhGelbvgqFNPLFFzG7Fh6igDAtfBr205juWBcc/WuvsLJdO02OJd3LEjHaptbkDT+YpwwpJr79xHGwH3Qc+9AFm6t/tNkPnJwMc9a5a5vX069igAOxz1rfe9/fpGvC7cnisbU/IllBcgEHINAF59SmIb5RtHT3pLeVlnGVCiTk49ap3Go2lrZl5Dnb39ay01qN5YyM4+8MnjNAHavYq6+cQCR61XjLQhljx15rlLnxvDbcA7uxHaqyeN9NnuBDLP5TEZORx+dAHQXbtcyujf6vvjvWro9tFb22zaADzWNZ3NtdCN4ZAUJ7HrXQvlINy9AOMUAJ9mguZSXCqy9DTNThjEG0yg8dPWuX8T65/Z0aTs2wKecd65W58XLLEcXJcP3zjFAG5P4ct725M96ikDgD2rivFOiWNqZXt4xGV5GK77Qtd06WyTz5g7Y+tcX8RL+1kLpYnDMOQOlAHnE6hjmMZpYyFUBh3qEpNGx4PPtSo7BhmgDrPCYCeY3Rga7W11trZvmdQoHNcb4fuYDGdufNxjFV9btrpVaVyRHnoKAN/WfEsc94q78noStbS2ttfWEIk2h2OQRXlcKMX3DNdXpNxLHEjB2PPegDd1HRI7XDpkA9q37O0gt9IR5IwSw5OOa5mXU5JiombOOlWZNWnktlh3fKO1AFa4+S4bBBTPFRGQhlZ2OD0olcsOcVEuG684oAtI2ZFweMiikXKsmB3ooA+r8UEUo+tLigBhFGPWnUmKAGkU0in01qAIzVS9lEUEjt0VSatOa4X4qa4dH0NREw82dwgz6d6APOfFek3OqXz3IbCMc8ViSaB5UmZHzgA9f0rtdI1q0OlyXE7qNq8hq4bXPEi3Mg8oDZnGRQBZt8QEhF5xir+kWAvA5DYKdfese21K3ZfmYZx3q9ZXUkTs1u2A4xxQB6N4d8owpGpBZeK3o9CS4uknuTuVPup2z71heDdOmdIJXwq53e5rv1UAUAQrEFUADAoKCp8UmKAKskQI6VQmhHIxkGtYjioHTJOcUAcfqulo+8qoyRVbTIPKj2j+HiuuubcMpBFZL2yxFiOAe1AGLfW4kk3Fgo71gavrdnZSIkh3EcKBWxrV0I+OQa861O1F3qbK55U8kHtQBZ1HxXOWYWkJHGMmsr+1bydd0zYJ96ZeW/wBnBVFLVQcMjLkkH+VAGwRJNA4dizFc/jXL3V7dwIFR2UAnj0retwRGrPIeOcZqpqU9iz7XSQseSV6UAcvd6i86qCuH9ayJr79++4/w9a1PE7Q2KLLbR7g/IB7Vw9zeu8hfaFzxxQB1mjeKL/TZQYZzsBztJyK9P0z4oLJAouk2nHOOhrwWC42oQUOTjB9K0YptyYRue4zQB6b408X2+sWPlJwVOR9a8+lnlYDJ49apncTzmrUZBAGOKANjRNYmsD8pyp6irN3qYvHY5AJ9axdq8AZzU0UY5HrQBsWkquvlyAMPU1Uv7cKQ8eApOKqbjGw2GpGuGdQp7UAX9NP2RzI/THGK0bnUGvIDETgDpWDudgACcVZtY2zmgCxbxNuIPFa9opVcc1DaQjqw/GryLgdKAAnJqaFuQpqEA54qVV5GaALDj5eKbGhDH0FSRnj5utWoogVz1oAghcbl+tFL5e2YcdxRQB9YClpAaTPNAAetIetKT6UwmgAJpDSE0hNAEchxXinx1vM3Gn268kZc17PM2FNfOnxN1NbnxdcAtuSLEYoA56aeSXTRHnaOhA71mSwbIdyv06rWzo9n/aBlRDggZHvTv7J+yxTSz5JUdMcUAcmrzmb5cgZ611nhe6MV4gkBZR1zXKSTM87nPetLSbtxcIV4P0oA+lfCjb7dfTGR7V0orhfAl+DYRiUgPgZNdypyAe1ACkZwfSkIp2aYzDFADH6Gqsx2k88Ul3cCDLNwnr2rCv8AWoireTIrHpxQBpNcgEoDkiqlzMhUgnBrDtNUO5nlIAzge9Q32oeZISo4x2NAEesRLMjYIya5m308C6JkPf0rXkuctgE0yK4WSUpwcck0AZeoafE0Jn7D5W9q5g6clxccHpXfzSw/ZrkMEK4yK4W7vUt5T5agHPUUAXToyhNzlceorA1q3hhZOMenFPuNblf5Vxn35rKvp7iSNtzbu44oAxPFcOYIzH8yHtXnlwuJGBGOa7/VFuJbU7jwORXF3cBDE+/NAFWNMgkE8DJqWEHsce9IVIU9qfCCFFAGjbyBkAY8j0q9Gi/KFOayI91aFvJtOST70AXSvpSKxBIB5pwkBHBoUfMaADbuI7VMkRJoRSTzV61Uhh6UAMggJPStS3gCckVZggBGQKsBPlJx9RQBHFkLjFTqeOaRVH5U8+mOKABTU8ZBGDUO3B4oDFTQBYHDZ5q9A+F9M1mhySKsCTGOuKALEgzIuD3FFEXOMnvxRQB9UCj8aYDSjrQAH60hNBpKAEzTGNOJqGVwiFmIAHJJoAwvGesxaLod1dyMAVUhBnq3YV8rSyTX+oyTTMS8jliT7mu9+K/ieTWtUe1t2/0G3bAwfvH1riNNhJl8yQkKDkn2oA7XwtCtpiSd1BHGazvHviAKhtLSRX/vMlWNYmhl0cy2Ey4iXlR1PvXnanfc4c8k/WgBiyMEZ3Bya1PD84e7RNpYk9hWLfArMU3HA/WvZPg/4TgubL7fMNxIwMjpQBt6KJlhjeIFVUCvRvDmofb7LcR86Ha1UU0nypBhV8pRVdHl0i7RYYwYZPmYD170AdWWqNiM1Ekolj3qeDTQSPmY8UAJdRJPC0ciB0bgg1zF94fS3UNAP3eeh6iuvXB6Uk0YeMqRkEUAcC+mYi61QkscMcniuucbHKOg44rG1CdbeQqQBj2oAwmswCc547022tkCyMqncKS+1N/mKHgdzWFF4gmiuWBwUoA6K5sQbBj/ABMfzritQ04faGKx559av6z4hk+yt5bMqg4A9a4241V3csGOTx1oA2rHRRcXYUxcdeDV268ONIuI22AetZHh25na7LRsxOMYNdpBPB5ex/mYj5vagDkJ/D7rbOrAPlcZXnFeY6zpslveSI4xg19FR29qLKSeMcba828XaUt2rzQLl1+8PWgDyWW3IJAGRSRpg8CuiOkTMCVRj+FUptPliPzIfyoApRx5HSrCLxUkcRBwasLF09aAGRrkirCLg0IhBFWEjIwcdaAFjXkcVftwPxqvFHkirEXDUAbFswCCriAckVmW79BWrHIAAMDpQAjR7ce49Kd5QABapfMSQbSfpQFAHtQBEU5BHNN8v5eRVkjkYpCMdaAK4BXtTlODihn6ginRjIzigCeB/nUe9FMRcyrz0IooA+p0kBqXcK8e034sWjcXETBgccGtRvirpSR52Sk+mKAPTC1NLV45d/Gm0jJEOnyvjoWcCsO++M2ozBlsrOCHPdiWNAHu93dRW0TSTyLHGvJZjgCvIfiD8QVukk07Rn/dH5ZJwevsP8a851rxXrOunF9ds0fXYvCj8KyZZtg4oAlvvLjjO45Y8/Ssk3mzIJ3JjG0U7UnbC5bORzg1lE/Pk9KAO++GG2+1iW2aINCYjuU8iqnjrwdc6Pf+fZozWrkn5RnZXR/CKaxsoLiWV1W5c5XPUrXdXV3BrltNEoYAqVDf1oA+c7aCS8vkijVnd2CgYr6f8C2X9i6Fb2iqSyrk/WvPfh34GuINblur2P5YmPl5H3vevZHiEMIIABAoAHeZ1B4ALc/SsvxNqUNlavK6bti8EdRT7LUVvDNHE/Eb7cnjmnppK3DM1zJu3dsdqAOC0vWtQ1jWo7e1leKzUZeQdMntXpGn29xEhVpzJnoW7VWs9FtNPnfyIlRGO7AFbKYCjaOKAHpuVQDjNBajO6sjxDqYsLZioy5HHtQBmXl6z3rxj7pJwfSuO8X3UlsgcZxnBrQF4ZJUbcSTzWN4hlFzEyzOAOw9aAOXmvn8vdvyD1Gaxry/VXNVNQkaCWRI33H+EVz11cXLuBKrflQBvyahHIxjkYgdsmqZmiaXEZzk4qt/Zt3JCJghRCM896q28TpMctigD0XwjboDu4DAZqvcXksd6y/NjJFV/DV+yzRo+SuOo71q21j9q1GUMcYJAxQBr2zu2iDbuw7YqvaW0LqRMc56it54ks/D6b8Daa5BrtVutqvjNAGlbx2sVyYdi88dKraxodjOrrCnzN3qO+YmRNud2OTW9osSSxKSCSKAPKdf8Ptpx34+Q1iRwkt0r1/xXaJOPLZRXGz6ZFE+wrj3FAHOR25zyOKtrCAnzCtuPSt6kqwyOxqK4s3jVdy4FAGd9nxGGxxioVGGrpLmxK2KkDkjNYfk89OaAHwfeUVpkfKMdaisLYySqAK13s2RunNAFCMYGSKtCQYBxz3qdoNu3K81EVJfgUAKPmyVoCE53A5qZE24BqUDJ2kcmgDPkQbge9PAIHTirjW37zBU0G3IyDx6UAVoI2eQYGeaK0rRVjIz1yOlFAHl6XJSViCc5NXTdO6gljmslv8AWtj1NSpuB7mgCwTkkkmpIySvy8e9Q84zipI+RQBYR2GPmpsk+6TocAVGuQ+AKnyEyWUDI70AQbzJuDdMcUxYgSGBBx1FSnZIDtIzVdlCZ+cCgDqr77NYaXZXFpODKMMwHY9xXcfD27+2X6Q7ziTBzmvGpZHkQLu3AdBXUeEL660vZcQMSVPHtQB9TwQpHEFUAYGKoatcJDGUkbbuGB7mvOvC/wAQri9vvsdxjPZjxXZ28i6kWFxg7W+X296AMSEOl15aAsCeMCu3sIm8ld+c4qpY6ZDFkyAM3Zq0llSJcZ6cUANuoiy5XqOa53VfE9jpTlLuULIP4eprpJ5gsDOvOBmvJviJo7apNDdWR2yMcOPWgDsLfxQLy1eW0X93nAY96pzs+oQ7nJPPINcjafaNJs0hlB2qO3eqmo+I7m3hHlnaSc/hQB0Ep+zCVgOg4zXAeItWZ5WDDGM9KytV8UX6Xe4ysyk8r2qreXBvYyzqBkdaAMt79ftDbsHPGTWlos0dxcRrIikbgCK56WBhLgrirujRzJfxhO9AHSa1qgeO6RUUNC+3gcbe1cS8zNOST0NdQqZ1eaOUfJNlD+Pesq40h4b5ogO/pQBY0ud4wCCe3NegaDfQTosjnbKO4HUVy0GjMunkYLSYGBU9qW060/fgj5sUAd1reoWs+ltDEru31ryy71p7aZ18kLIDjntXWaXqUN1OsagZ6c1Z1HwkmqTGTygMHkj0oAwdA1Ga+cBmB9eOleiWdvHDZBw5U+orFPhBLKwCWTESHkmprW/W0thaXhL443dxQBcvdOa6j3GeuF1GNoblkdt2CQDXVahqDRW5EDBgenNcjfmQqZHByD3oAnsZwB8/Sre9ZnCAjHpWC1wAgx3qaynxJuLc0AdddmBbLaQCQMVjixgkTdgiq89w8sYBJxmrdmWlKItAG94a0WBt0zZIHStafSYH6ZWnaavkWqqvepbi4ZRwKAKR0WEt8sgB96qT6LAuf3vPsKuG4bf04qvI7SyYAOO1AEf9mWyxqwdiehpLiCyhjD7TkHqTT5GCRsrDjGetZt0DNFgcKP1oAtPLE8ZZVXp19Kx7qUtLwelIrNGdu7jvUUxG4k9fWgB0UreYBnvRVXzQGXHBzRQB50wxK31NWEcAVEw/etkdzUoXPagBysc4FSgYAJNQb9tMeUnIoAtG6CNhahmuTJnJqsM0hAxQBNHIc8HApJiGPWogaTPOKAHI2w5Fb+jajHDCyt970J61gtC/lF8HbnBOKiQ8jB6UAeyeDNGj+122o3B+R+VWvWBJAqlbf/WlcADvXzho/i670+KOBcNEnQN2rfj8ZXzazaXkEnAwGT+HHvQB6dq+palHZMLK5ZZIyOG746iug0e9e7sIZpGDMRng5qhK1nf2CyMFMrLuIFSeGTBaMLaNVCOSQM9DQBvb2Ns+eMqcA15bo2vBbu4iv2/1TkBW7c169NCjxFenFeWfEnw0jr9ssAI7vP3xxu+tAF3VTDeWuIWBJ54PWuL1G2DQvv8AvKcc9q4+bWtQs9yid0Zcgrmucur+8upGeSWQkn+8aAN3UIbZ5tjyEHqcDpVmKezVFQM54wOK5+0glaEyFmzUNxK6PjcaANm9mg+8q59M0aVqCQXO4oCVUnpWC88r9Txip7API8iKCSwwKANafXT5m9I13Zz0rQvdWdlhuo0jywyc1h2+jT3DH+EAc57UXm20AQ4ZQML6UAdFYeJbmV1QmNMHj5a6Ca9tZ4lW/g8wnuvFeawM5cNHwSa9O0PTvt1lDzlsdKAINLsrOa9LRwyxhOmGrrra/uLVQohJXoS3XFZQlhs9RggYKp7+9auuataWUJVSpZhwBQBtQ6lZGJVZlEjfwk1i6vbabcMd3ykc5U15tD4iS5vn+1Zj28A5q3HrlubtGSQ7R1yetAFnW5ILJ9kG9vQnpWXqV6txahFUiRqu6jc293JuBG31FNtrKCZhkZ560Ac+kbNGowcg4NTxx7H711P9nwKwjVakbR41JbbnvQBgwkvtU5xXQ6PEgkX5l+uazZrbbkcKPaoYX8qQlHJoA9GheMjAYYAprMrMw6iuSs9QKcuxrQs9SVt/IB9M0AW7txHkAiqr3ZCjA/EVnXl7tnLhs/0rPl1EfNyDQBpXF2wALt3zVM3eSwB6nrWdNdeZxn5aoSSsknB4oA2nlJyxwcdaqy3PIwapx3fynJqF5twz3oAuGTdKpB7iiqUc2ZV+oooA5ZyfNbHqakDiopP9a31NFAAzZc1GW+Y80P60z+VADifejPXmmCloAfmlB5BHWogTmp4lyRQBt2Fzavp8kN1kSY+XHesJtquSvTPepLgqkfB+aqsU6OQJOvrQA6SXJxnFaOk34hBR/mDdPas++WKMBom4I5zVeKZV780Ael2HjGfTIAit5oxgA+lS2fj+6gvRcCFSV/hLcV50tzvZSc+mKtomcFTQB7ZoXxTvNRvYraW0ijMnAYNwK2NR1RruxmSVsuPmArwyxv0tby2dx9xgTiuvfxRDbXETPL5kTdgc8UAcze2t/qWpSN9mkLyOeiYFasPhOdJESaPYwG4g12un+Io9QAWyjVY4xk8YyavwGSZlnuFUHpx6UAcZY+HttqVc85PAFYOqeHvLlcksFA64616hZyo+9NoDA556GuV8cXphUCEIWzkkUAefT6aYsEscVWRmjlxECpHcmm3NzK7tukYg9s1U3lmPJ/OgDrrfUP8AR32BVkddrZPBqsscN4hjkdd31/lXPqxB5NWYXKEMuc0AdbougJ56RvhgxxnNeweFvDyWuw5G0DnmvJPCV1LNewox4BBNezwX6QabvUgY460AZPjbQtPY+fvaOYKcMvWvGfET3ljG0iXHnRBurD5h6V6zqGox6pIbcSKcDNeQ+NZFN21tESABhvrQBzz3fnHfJgP1OO9Pgnxk7qyH3ISD2709ZT0z+tAG4l66j5HNaenarIhAZiRXLRycnBqxFLjFAHpelamk0qbsntXSORztJxivJrG7khdWRuc13FvqRnt1Qn5sZNAD9Xbacr/OshJDzn1qW+uAzgE81SkcdaAH3N2ynap6elJb3rK55rPmb5sk1GGy3DUAbrXBeJuRzWY7ncetJE5wOc4pJm596AF83GQTUUkpIOaiLYJOeajL55oAf5hB609ZSR1qqze9KjUAXI2/eJz3FFV4m/ep9RRQBmSxv5j/ACN1PamFHx91vyoooAa0b/3G/KozG/8Acb8qKKAFET5+635UrRPk/I35UUUANET5+435VMiuo+63X0oooAq3u/B+Vvyqid4xhGz9KKKAHlZWjztc49qiEchI+R8fSiigC5EjAD5Hz9KtwNKCfkPPtRRQBYELNl2Vs/SkYcj5GOPaiigDsPC18Fg8tUZWDAEY6iu+E7lIwCdpHpRRQBUlMiFzGDyetcz4uhkGGKNh0yeO9FFAHnksbhmBRsfSoxEQc7Gz9KKKAE2ybuEb8qkUSjGEb8qKKAOn8Leek6tsbOcdK9F8Rap9i0WONBmR1GRRRQBxukasDfqyq4Y9Rg1x+u3Ly6ncvtblzjiiigDJdXwcxtn6VDtbP+rb8qKKAHxxvydjflVhI3wCEb8qKKANKzVldcoxH0ro4mZF3BWGBxxRRQBVnlZp/utnvxTWd2zhT+VFFAFOTzcn5W/KowX/ALrZ+lFFAE1vI6nlWx9KsSBnG4BvyoooAqMHycq2fpRtb+635UUUABRj/C35UgVx/C35UUUAWLaNvNT5G6jtRRRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe pancreatic duct changes with dilation of the main pancreatic duct and of the primary and secondary branches.",
"    <div class=\"footnotes\">",
"     ERCP: endoscopic retrograde cholangiopancreatography.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK, 1997. Copyright &copy; 1997 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_31_9727=[""].join("\n");
var outline_f9_31_9727=null;
